Global Clinical Development -General Medicine 
Secukinumab (AIN457)
Clinical Trial Protocol CAIN457F2366 / [STUDY_ID_REMOVED] 
A randomized, double- blind, activ e control, multicenter 
study to ev aluate the efficacy at week 52 of subcutaneously 
administered secukinumab monotherapy compared w ith 
subcutaneously administered adalimumab monotherapy in 
patients with acti ve psoriatic arthritis
Document type: Clinical Trial Protocol 
EUDRACT number: 2015 -004477 -32
Version number: v02 (Clean)
Clinical trial phase: IIIb
Release date: 24 Feb 2019 
Property of Novartis
Confidential
May not be used, divulged, published, or otherwise disclosed
without the consent of Novartis
Clinical Trial Protocol Template Version 3. 1 (February 2016)

Novartis Confidential Page 2
Amended Protocol Version 02 Clean Protocol No. CAIN457F2366
Table of contents
Table of contents ................................................................................................................. 2
List of tables ........................................................................................................................ 5
List of figures ...................................................................................................................... 6
Amendment 02 .................................................................................................................. 13
Amendment 01 .................................................................................................................. 14
1 Introduction ............................................................................................................ 22
1.1 Background ............................................................................................................ 22
1.2 Purpose .................................................................................................................. 22
2 Study  objectives and endpoints ............................................................................. 23
2.1 Primary  objective ................................................................................................... 23
2.2 Secondary  objectives ............................................................................................. 23
23
3 Investigational plan ................................................................................................ 24
3.1 Study  design ........................................................................................................... 24
3.2 Rationale for stud y design ................................ ................................ ..................... 25
3.3 Rationale for dose/regimen, route of administration and duration of treatment ....25
3.4 Rationale for choice of comparator ....................................................................... 27
3.5 Purpose and tim ing of interim anal yses/design adaptations .................................. 27
3.6 Risks and benefits .................................................................................................. 27
4 Population .............................................................................................................. 28
4.1 Inclusion criteria .................................................................................................... 28
4.2 Exclusion criteria ................................................................................................... 29
5 Treatment ............................................................................................................... 32
5.1 Study  treatment ...................................................................................................... 32
5.1.1 Investigational and control drugs .......................................................... 32
5.1.2 Additional treatment .............................................................................. 32
5.2 Treatment arms ...................................................................................................... 32
5.3
Treatment assignment and randomization............................................................. 33
5.4 Treatment blinding ................................................................................................. 34
5.5 Treating the subject ................................................................................................ 35
5.5.1 Subject numbering ................................................................................ 35
5.5.2 Dispensing the investigational treatment .............................................. 35
5.5.3 Handling of study  treatment .................................................................. 35
5.5.4 Instructions for prescribing and taking stud y treatment ........................ 36
5.5.5 Permitted dose adjustments and interruptions of study  treatment ........ 37

Novartis Confidential Page 3
Amended Protocol Version 02 Clean Protocol No. CAIN457F2366
5.5.6 R escue medication ................................................................................ 38
5.5.7
Concomitant medication ....................................................................... 38
5.5.8 Prohibited medication ........................................................................... 39
5.5.9 Discontinuation of study  treatment ....................................................... 42
5.5.10
Withdrawal o f consent .......................................................................... 43
5.5.11 Loss to follow -
up .................................................................................. 43
5.5.12 Emergency  breaking of assign
ed treatment code .................................. 43
5.5.13 Study  completion and post -study  treatment .......................................... 44
5.5.14 Early study termination ......................................................................... 44
6
Visit schedule and assessments ............................................................................. 44
6.1 Inf
ormation to be collected on screening failures.................................................. 53
6.2 Patient demographics/other baseline characteristics ............................................. 53
6.3 Treatment exposure and compliance ..................................................................... 53
6.4 Efficacy .................................................................................................................. 54
6.4.1 American College of Rheumatology  (ACR) response .......................... 54
56
56
57
57
58
58
6.4.8 Psoriasis Area and Severity  Index (PASI) ............................................ 58
60
6.4.10 Appropriateness of efficacy  assessments .............................................. 60
6.5 Safety ..................................................................................................................... 61
6.5.1 Physical examination ............................................................................ 61
6.5.2 Vital signs .............................................................................................. 61
6.5.3 Height and weight ................................................................................. 61
6.5.4
QuantiFERON TB- Gold test or PPD skin test ...................................... 62
6.5.5 Laboratory  evaluations .......................................................................... 62
6.5.6 Electrocardiogram (ECG) ..................................................................... 63
6.5.7 Pregnancy  and assessments of fertility ................................................. 63
6.5.8 Tolerability  of Investigational Treatments ............................................ 63
6.5.9 Additional parameters ........................................................................... 64
64

Novartis Confidential Page 4
Amended Protocol Version 02 Clean Protocol No. CAIN457F2366
6.5.11 Appropriateness of safety  measurements .............................................. 64
6.6 Other assessments .................................................................................................. 65
6.6.1 Health
-related Quality  of L ife............................................................... 65
6.6.2 Resource utilization ............................................................................... 67
67
68
69
7 Safety  monitoring .................................................................................................. 70
7.1 Adverse events ....................................................................................................... 70
7.2 Serious adverse events ........................................................................................... 72
7.2.1 Definition of SAE ................................................................................. 72
7.2.2 SAE reporting
........................................................................................ 73
7.3 Liver safety  monitoring ......................................................................................... 74
7.4 Renal safet y monitoring ......................................................................................... 75
7.5 Reporting of stud y treatment errors including misuse/abuse ................................ 75
7.6 Pregnancy  reporting ............................................................................................... 75
8 Data review and database management ................................................................. 76
8.1 Site monitoring ...................................................................................................... 76
8.2
Data collection....................................................................................................... 76
8.3 Database management and quality  control ................................ ............................ 77
8.4 Data Monitoring Committee .................................................................................. 77
8.5 Adjudication Committee ........................................................................................ 78
9 Data analy sis.......................................................................................................... 78
9.1 Analy sis sets .......................................................................................................... 78
9.2
Subject demographics and other baseline characteristics...................................... 78
9.3 Treatments ............................................................................................................. 79
9.4 Analy sis of the primary  variable(s) ....................................................................... 80
9.4.1 Variable(s) ............................................................................................. 80
9.4.2 Statistical model, hy pothesis, and method of anal ysis.......................... 80
9.4.3 Handling of missing values/censorin g/discontinuations ....................... 80
9.4.4 Supportive analy ses............................................................................... 81
9.5 Analy sis of secondary  variables ............................................................................ 81
9.5.1 Efficacy  variables
.................................................................................. 81
83
9.5.3 Safety
 variables ..................................................................................... 84
85

Novartis Confidential Page 5
Amended Protocol Version 02 Clean Protocol No. CAIN457F2366
86
87
87
9.6 Interim anal yses..................................................................................................... 87
9.7
Sample size calculation.......................................................................................... 87
10 Ethical considerations ............................................................................................ 88
10.1 Regulatory
 and ethical compliance ........................................................................ 88
10.2 Informed consent procedures
................................................................................. 89
10.3 Responsibilities of the investigator and IRB/ IEC.................................................. 89
10.4 Publication of study  protocol and results ............................................................... 90
11 Protocol adherence ................................................................................................. 90
11.1 Protocol amendments ............................................................................................. 90
12 References .............................................................................................................. 91
13
Appendix 1: The classification criteria for psoriatic arthritis (CASPAR) ............. 94
14 Appendix 2: Guidelines for administering the questionnaires for patient 
reported outcomes ..................................................................................................................... 95
15 Appendix 3: American College of Rheumatology  (ACR) Measures and 
Criteria of Response ................................................................................................................. 98
100
17 Appendix 5: The Psoriasis Area and Severit y Index (PASI )
............................... 101
18 Append ix 6: L iver event and laboratory  trigger definitions and follow -up 
requirements ........................................................................................................................... 103
19 Appendix 7: Clinically  notable laboratory  values ............................................... 106
List of tables
Table 5
-1 Blinding scheme .................................................................................... 33
Table 5
-2 Prohibited medica tion........................................................................... 39
Table 6
-1 Assessment schedule ............................................................................. 46
58
Table 6
-3 The PASI  scoring s ystem................................ ................................ .....59
64
68
69
70
Table 7-1 Study  treatment ................................ ................................ ..................... 75
Table 9-1 Assumption for sample size and power calculation.............................. 88

Novartis Confidential Page 6
Amended Protocol Version 02 Clean Protocol No. CAIN457F2366
Table 9-2 Power for superiority  tests for primary  and secondary  endpoints 
(two-sided, α=0.05) ............................................................................... 88
100
100
Table 17
-1 PASI  Scoring Worksheet .................................................................... 101
Table 18
-1 Liver Event and Laboratory  Trigger Definitions ................................ 103
Table 18-2 Follow up Requirements for L iver Events and Laboratory  Triggers ..103
Table 19-1 Clinically  notable laboratory  values .................................................... 106
List of figures
Figure 3 -
1 Study  design ......................................................................................... 25
Figure 9 -
1 Testing Strategy .................................................................................... 82

Novartis Confidential Page 7
Amended Protocol Version 02 Clean Protocol No. CAIN457F2366
List of abbreviations
ACR American College of Rheumatology
AE Adverse Event
ALT/SGPT Alanine aminotransferase / serum glutaminc p yruvic transaminase
ANA antinuclear antibody
anti-CCP anti-cyclic citrullinated peptide
anti-dsDNA anti-double stranded DNA antibodies
AST/SGOT Aspartate aminotransferase / serum glutamic oxaloacetic transaminase
BSA body  surface area
BSL baseline
CASPAR Classification criteria for Psoriatic Arthritis
CCP cyclic citrullinated peptide
cDMARD conventional Disease modify ing anti-rheumatic drugs (also known as 
non-biologic DMARDs)
CFR Code of Federal Regulations (U.S.) 
CPO Country  Pharma Organization
CRF Case Report/Record Form (paper or electronic)
CRO Contract Research Organization
CTC Common Toxicity  Criteria
CV Cardiovascular
DMARD(s) disease -modify ing antirheumatic drug(s)
ECG Electrocardiogram
eCRF Electronic Case Report/Record Form
EDC Electronic Data Capture
EMA/EMEA European Medicines Agency
ESR erythrocy te sedimentation rate
EU European Union

Novartis Confidential Page 8
Amended Protocol Version 02 Clean Protocol No. CAIN457F2366
FAS full analy sis set
FDA (U.S.) Food and Drug Administration
GCP Good Clinical Practice
GGT gamma -glutamy l transferase
HAQ- DI Health Assessment Questionnaire –Disability  Index
hCG human chorionic gonadotropin
HDL high densit y lipoprotein
HIV human immunodeficiency virus
hsCRP high sensitivity  C-Reactive Protein
IB Investigator Brochure
ICF informed consent form
ICH International Conference on Harmonization of Technical Requirements 
for Registration of Pharmaceuticals for Human Use
IEC Independent Ethics Committee
IL interleukin
IL-17 Interleukin 17
IRB Institutional Review Board
IRT Interactive Response Technology
IUD intrauterine device
IUS intrauterine s ystem
IVR Interactive Voice Response
LDL low density  lipoprotein
LFT Liver function test 
LLN Lower limit of normal
LLOQ lower limit of quantification
MAR missing at random assumption

Novartis Confidential Page 9
Amended Protocol Version 02 Clean Protocol No. CAIN457F2366
MedDRA Medical dictionary  for regulatory  activities 
mmHg millimeter of mercury
MMRM mixed -effects repeated measures model
MRI magnetic resonance imaging
MTX methotrexate
NSAID non-steroidal anti -inflammatory  drug
OC/RDC Oracle Clinical/Remote Data Capture
PASI Psoriasis Area and Severity  Index
PFS prefilled s yringe
PoC proof of concept
PPD purified protein derivative
PRN as required
PRO Patient Reported Outcome
PsA psoriatic arthritis
PSO psoriasis
PUVA psoralen ultraviolet light A
QTcF Fridericia QT correction formula
RBC red blood cell
RF rheumatoid factor
SAE Serious Adverse Event
s.c. subcutaneous(l y)
SJC swollen joint count
SmPC Summary  of Product Characteristics
SUSAR Suspected Unexpected Serious Adverse Reactions

Novartis Confidential Page 10
Amended Protocol Version 02 Clean Protocol No. CAIN457F2366
t.i.d. three times dail y
TJC tender joint count
TNF tumor necrosis factor
TNFα tumor necrosis factor alpha
ULN upper limit of normal
UV ultraviolet
UVA Ultraviolet light A
UVB Ultraviolet light B
VAS visual analog scale
WBC white blood cell
WHO World Health Organization 

Novartis Confidential Page 11
Amended Protocol Version 02 Clean Protocol No. CAIN457F2366
Glossary  of terms
Cohort A specific group of patients/subjects fulfilling certain criteria
Control drug Drugs(s) used as a comparator to reduce assessment bias, preserve 
blinding of investigational drug, assess internal study  validit y, and/or 
evaluate comparative effects of the investigational drug
Dosage Dose of the stud y treatment given to the patient in a time unit ( e.g. 
100 mg once a day , 75 mg twice a day )
Electronic Data 
Capture (EDC)Electronic data capture (EDC) is the electronic acquisition of clinical 
study  data using data collection sy stems, such as Web- based 
applications, interactive voice response sy stems a nd clinical 
laboratory  interfaces.
EDC includes the use of Electronic Case Report Forms (eCRFs) 
which are used to capture data transcribed from paper source forms 
used at the point of care.
Enrollment Point/time of patient entry  into the study  at which in formed consent 
must be obtained (e.g. prior to starting an y of the procedures 
described in the protocol)
Epoch
Replaces the term 
“Period” previously  
used for NOVDD 
studiesA portion of the study  which serves a specific purpose. Ty pical 
epochs are: screening/recruitment, wash- out, treatment, and follow -
up
Investigational drug The drug whose properties are being tested in the study ; this 
definition is consistent with US CFR 21 Section 312.3 and is 
synony mous with “investigational new drug” or “invest igational 
medicinal product.”
Medication pack 
numberA unique identifier on the label of each investigational drug package
Part A single component of a study  which contains different objectives or 
populations within that single study. Common parts within a study  
are: a single dose part and a multiple dose part, or a part in 
patients/subjects with established disease and in those with newl y-
diagnosed disease.
Patient/subject I D A unique number assigned to each patient upon signing the informed 
consent 

Novartis Confidential Page 12
Amended Protocol Version 02 Clean Protocol No. CAIN457F2366
Randomization 
numberA unique identifier assigned to each randomized patient, 
corresponding to a specific treatment arm assignment
Source 
Data/DocumentSource data refers to the initial record, document, or primary  
location from where data comes. The d ata source can be a database, 
a dataset, a spreadsheet or even hard -coded data 
Study  drug/ 
treatmentAny single drug or combination of drugs administered to the patient 
as part of the required study  procedures; includes investigational 
drug (s), placebo/ comparator active drug run -ins or background 
therap y
Study  Treatment 
Discontinuation 
(TD)When the patient permanently  stops taking study  treatment prior to 
the defined stud y treatment completion date 
Variable A measured value or assessed response that is determined in specific 
assessments and used in data anal ysis to evaluate the drug being 
tested in the study
Withdrawal of 
consent (WoC)Withdrawal of consent from the study  is defined as when a patient 
does not want to participate in the study  any long er, and does not 
want an y further visits or assessments, and does not want an y further 
study  related contact, and does not allow anal ysis of alread y 
obtained biologic material

Novartis Confidential Page 13
Amended Protocol Version 02 Clean Protocol No. CAIN457F2366
Amendment 02 
Amendment rationale The estimands described in Section 9.4.3 have been clarified to align with 
the study  objectives, which are comparing efficacy  of secukinumab monotherap y with 
adalimumab monotherapy.
In Section 9.4.4 , the non-parametric regression ( Koch 1998) model is not essential to the final 
analysis but may  be performed.
In Section 9.4.4, as it is expected to have few patients who discontinue treatment but remain in 
the clinical trial without rescue medication, it may not be necessary  to examine the effect of 
them on the primary  endpoint by using sensitivity  analysis. Sensitivity  analyses will be 
conducted to examine the effect of taking concom itant treatment of MTX and/or other 
cDMARDs along with study  drug.
Changes to the protocol
In Section 9.4.3 , the latter part of the first sentence, regardless of adherence to randomized 
treatment” has been deleted. A dditional changes to the sentence have been made to clarify  the 
estimand and the definition of monotherap y response has been added. 
In the second paragraph of Section 9.4.4 , “ACR20 response at Week 52 will also be e valuated” 
has been changed to “ACR20 response at Week 52 may  also be evaluated”.
In the last paragraph of Section 9.4.4, “and the effect of treatment discontinuation without 
rescue medication” has been changed to “ and/or the effect of treatment discontinuation without 
rescue medication”.
Institutional Review  Board (IRBs)/Independent Ethics Committee (IECs) and 
Health A uthorities
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Inde pendent Ethics Committee (I ECs) and Health Authorities.
The changes described in this amended protocol are non-substantial and do not require IRB/IEC 
approval prior to implementation.
The changes herein do NOT affect the trial specific model I CF.

Novartis Confidential Page 14
Amended Protocol Version 02 Clean Protocol No. CAIN457F2366
Amendment 01 
Amendment rationale 
At the time of this amendment no subjects have been randomized in the study . No change to 
the study  population is proposed by  this amendment. 
This protocol amendment is primarily  issued for the following reasons:
1.The half-life ofadalimumab is reported to be approximately  2 weeks, therefore in the 
original protocol the safety  follow -up was planned to cover 5 x the half-life or 
approximately  10 weeks. Consequently, the safet y follow -up visit was scheduled for 10 
weeks after last dose of adalimumab. Some Health Authorities have mandated that the 
safet y follow -
up for adalimumab be extended to 4 months after last dose of adalimumab, 
to be consistent with the Humira®SmPC 2016 .  
2.Exclusion Criteria 2 provided guidelines and examples where local label requirements 
for contraception use, after the last dose of study  treatment, should be followed by 
women of childbearing potential. Health Authority requests have been received that the 
protocol should specify  contraception use for five months after last dose of adalimumab 
(see Humira®SmPC 2016 ).
Changes to the protocol
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underlined for insertions.
The wording of “Visit Schedule and assessments” (Section 6), “Study  Design” (Section 3.1) 
and the “Study  Design” section in the “Protocol Summary ” have been amended to extend the 
follow -up period. Table 6-1“Assessment schedule”,  
 
The wording of Exclusion Criteria 2 ( Section 4.2) and “Informed consent procedures” ( Section 
10.2) has been updated with guidelines for cont raception use after the last dose of study  
treatment, for women of childbearing potential.
The wording of “Permitted dose adjustments and interruptions of study  treatment” (Section 
5.5.5) and“Prohibited medic ation” (Section 5.5.8) have been updated to extend the interruption 
requirement if the patient receives a live vaccine. “Study completion and post study treatment” 
(Section 
5.5.13) has been updated to extend the recommended time before starting a new 
biologic. These changes were made because elimination of adalimumab may take up to 4 
months.
The wording in the following 
Sections, “Purpose and timing of interim analy ses/design 
adaptations” (Section 3.5 ), “Prohibited medication” (Section 5.5.8),  
, “Interim analy sis” 
(Section 9.6) and “References” (Section 12) have 
been amended.

Novartis Confidential Page 15
Amended Protocol Version 02 Clean Protocol No. CAIN457F2366
Institutional Review  Board (IRBs)/Independent Ethics Committee (IECs) and 
Health A uthorities
A cop y of this amended protocol will be sent to the I RBs/IECs and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation. 
The changes herein affect the Informed Consent.  Sites are required to update and submit for 
approval a revised Informed Consent that takes into account the changes described in this 
protocol amendment. 

Novartis Confidential Page 16
Amended Protocol Version 02 Clean Protocol No. CAIN457F2366
Protocol summary
Protocol number CAIN457F2366
TitleA randomized, double -blind, active control, multicenter study  to 
evaluate the efficacy  at week 52 of subcutaneously  administered 
secukinumab monotherap y compared with subcutaneousl y 
administered adalimumab monotherap y in patients with active 
psoriatic arthritis
Brief titleStudy  of the efficacy  of secukinumab monotherapy  compared with 
adalimumab monotherapy in subjects with active psoriatic arthritis
Sponsor and Clinical 
PhaseNovartis 
Phase IIIb
Investigation type Drug
Study type Interventional
Purpose and rationaleThe purpose of this study  is to compare the safety  and efficacy  of 
secukinumab monotherapy  and adalimumab monotherap y in 
patients with active psoriatic arthritis (PsA) who are naïve to 
biologic therapy  for PsA or PsO and are intolerant or having 
inadequate response to conventional disease -modify ing 
antirheumatic drug (cDMARDs). Efficacy  will be evaluated based 
on multiple indices of improvement in signs and symptoms, physical 
function, quality  of life and patient reported outcomes. 
In PsA, more than half of the patients take biological DMARDs as a 
monotherap y with very good control of their disease. Similar 
outcome in response has been demonstrated with or without use of 
cDMARDs (including methotrexate). Thus 
no biologi cs have shown 
positive synergistic effects on any clinical outcomes and this is 
reflected in all their labels. Treatment with biologic monotherap y in 
PsA is therefore clinically  justifiable and avoids unwarranted 
exposure to the potential toxicity  of cDMAR Ds.
The randomized, double -blind, active control, multicenter, parallel-
group design used in this study  is in alignment with phase III trials 
of other biologics in this disease area and also in compliance with 
the European Medicines Agency  (EMA) guidelines on PsA trials.
Primary Objective(s) To demonstrate that the efficacy  of secukinumab monotherap y 300 
mg s.c.at Week 52 is superior to adalimumab monotherapy  (40 mg 
s.c.) based on the proportion of subjects achieving an American 
College of Rheumatology 20 (ACR20) response.
Secondary Objectives To demonstrate that:

Novartis Confidential Page 17
Amended Protocol Version 02 Clean Protocol No. CAIN457F2366
1.Secukinumab monotherapy  (300 mg s.c.) is superior to 
adalimumab monotherapy (40 mg s.c.) at Week 52, based on 
the proportion of subjects achieving PASI 90 response.
2.Secukinumab monotherapy  (300 mg  s.c.) is superior to 
adalimumab monotherapy (40 mg s.c.) at Week 52, based on 
the proportion of subjects achieving an ACR50 response.
3. The improvement (change) from baseline on secukinumab 
monotherap y (300 mg s.c.) is superior to adalimumab 
monotherap y (40 mg s.c.) at Week 52, for the Health 
Assessment Questionnaire – Disability  Index (HAQ -DI©) score.
4.Secukinumab monotherapy  (300 mg s.c.) is superior to 
adalimumab monotherapy (40 mg s.c.) at Week 52, based on 
the proportion of subjects achieving the resol ution of enthesitis. 
An additional secondary objective is to evaluate the safet y and 
tolerability  of secukinumab monotherap y (300 mg s.c.) compared 
with adalimumab monotherap y (40 mg s.c.) as assessed by vital 
signs, clinical laboratory  values, and advers e events monitoring.
Study designThis is a randomized, double -blind, active control, multicenter, 
parallel -group trial evaluating secukinumab monotherap y and 
adalimumab monotherapy  in approximately  850 subjects with active 
PsA. A screening period of up t o 8 weeks before randomization will 
assess subject eligibility . Efficacy  assessments will occur through 
Study  Week 52. Two follow -up visits at Week 60 and 68 will occur 
thereafter. Total maximum study  duration, including screening 
period, is up to 76 weeks .
At Baseline, subjects whose eligibility  is confirmed will be 
randomized to either Group 1 (secukinumab 300 mg as 2 x 150 mg 
s.c. injections), or Group 2 (adalimumab 40 mg as 1 s.c. injection) 
with approximately  425 subjects/group. In order to maintain the 
blind, both groups will receive 1 or 2 placebo s.c. injections to keep 
consistency  in the number of injections at each dosing visit. 
Secukinumab is available in 150 mg/1.0 mL pre-filled syringes 
(PFS) and adalimumab is available in 0.4 mL PFS. Placebo (1.0 and 
0.5 mL , PFS) is also available.
Group 1 - Secukinumab 300 mg s.c.
Secukinumab 300 mg (2 x 1 mL PFS) will be administered at 
Baseline, Weeks 1, 2, 3 and 4, followed by dosing every  4 w eeks 
until Week 48. In addition, all Group 1 subjects will receive placebo 
(1 x 1mL  PFS) at given visits in order to maintain the blind.
Group 2 - Adalimumab 40 mg s.c.
Adalimumab 40 mg (1 x 0.4 mL PFS) will be administered at 
Baseline followed by dosing every  2 weeks until Week 50. In 

Novartis Confidential Page 18
Amended Protocol Version 02 Clean Protocol No. CAIN457F2366
addition, all Group 2 subjects will receive placebo (1 x 0.5mL or 2 x 
0.5mL  PFS) at given visits in order to maintain the blind 
PopulationThe study  population will consist of a representative group of male 
or female subjects at least 18 years of age, fulfilling the 
Classification criteri a for Psoriatic Arthritis (CASPAR), and PsA for 
at least 6 months and have active PsA disease defined as >3 swollen 
and tender joints in spite of treatment with NSAIDs and/or 
cDMARDs. Subjects will be eligible to enter the study  if they have 
not previously been treated with biologic DMARDs (e.g., TNFα 
inhibitors), or cell-depleting therapies and either have previousl y 
been treated with cDMARD, including but not limited to MTX, with 
an inadequate response on therapy  or have stopped treatment due to 
safet y/tolerability  problems after at least one administration of a 
cDMARD.
Key Inclusion criteria 1.Informed consent must be obtained before an y assessment is 
performed.
2.Male or non- pregnant, non -lactating female subjects at least 18 
years of age.
3.Diagnosis of PsA as classified by  CASPAR criteria and with 
symptoms for at least 6 months and with active PsA at baseline 
defined as ≥3 tender joints out of 78 and ≥3 swollen joints out 
of 76 (dact ylitis of a digit counts as one joint each).
4.Rheumatoid factor (RF) and anti -cyclic citrullinated peptide 
(CCP) antibodies negative at screening.
5.Diagnosis of active plaque psoriasis, with at least one psoriatic 
plaque of ≥2 cm diameter or nail changes consistent with 
psoriasis or documented history  of plaque psoriasis.
6.Subjects w ith PsA should have taken NSAIDs for at least 4 
weeks prior to randomization with inadequate control of 
symptoms or at least one dose if stopped due to intolerance to 
NSAIDs.
7.Subjects who are regularly receiving NSAIDs as part of their 
PsA therap y are requ ired to be on a stable dose for at least 2 
weeks before stud y randomization and should remain on a 
stable dose up to Week 52.
8.Subjects receiving corticosteroids must be on a stable dose of 
≤10 mg/day  prednisone or equivalent for at least 2 weeks 
before ran domization and should remain on a stable dose up to 
Week 52.
9.Subjects must have previously  been treated with a cDMARD, 
including but not limited to MTX, with an inadequate response 
to therapy, or must have stopped treatment due to 
safet y/tolerability  probl ems after at least one administration of 
the cDMARD.

Novartis Confidential Page 19
Amended Protocol Version 02 Clean Protocol No. CAIN457F2366
Subjects who are receiving a cDMARD will be allowed to enter the 
study  only after cDMARD discontinuation and appropriate wash -out 
e.g. 4 weeks prior to randomization visit except for leflunomide, 
which has to be discontinued for 8 weeks prior to randomization 
unless a cholest yramine wash -out has been performed.
Key Exclusion criteria 1.Pregnant or nursing (lactating) women, where pregnancy  is 
defined as the state of a female after conception and until the 
termination of gestation, confirmed b y a positive human 
chorionic gonadotropin (hCG) laboratory  test.
2. Women of childbearing potential, defined as all women 
physiologicall y capable of becoming pregnant, unless they are 
using effective methods of contraception during dosing of study  
treatment and minimum 16 weeks or longer if local label 
requires it after the last dose (e.g. 20 weeks for secukinumab, 5 
months for adalimumab in the EU). 
3.Chest X -ray or chest magnetic resonance imaging (MRI) with 
evidence of on going infectious or malignant process obtained 
within 3 months prior to screening and evaluated by  a qualified 
physician.
4.Previous exposure to any biologic drugs for PsA and PSO, 
including but not limited to TNFα inhibitors, secukinumab, or 
other biologic drugs targeting IL -17 or IL -17 receptor.
5.Subjects receiving high potency  opioid analgesics including but 
not limited to methadone, hy dromorphone, and morphine.
6.Ongoing use of prohibited psoriasis treatments/medications 
(e.g., topical corticosteroids or ultraviolet therap y at 
randomization). 
7. Previous treatment with any  cell-depleting therapies including 
but not limited to anti -CD20 or investigational agents.
Investigational and 
reference therapyInvestigational treatment:
Secukinumab 150 mg, liquid formulation in a PFS (2 x 1 mL PFS 
for 300 mg dose)
Reference treatment:
Adalimumab 40 mg, liquid formulation in a 0.4 mL PFS
Placebo, liquid formulation in a 1 and 0. 5 mL  PFS
Efficacy assessments American College of Rheumatology (ACR) 20, 50  
responses
 

Novartis Confidential Page 20
Amended Protocol Version 02 Clean Protocol No. CAIN457F2366
 
 
Psoriasis Area and Severity  Index (PA SI)
 
Key safety 
assessments Evaluation of adverse events/serious adverse events
Physical examination
Vital signs
Height and weight
QuantiFERON TB- Gold test or PPD skin test
Electrocardiogram
Local tolerability  (injection site reactions)
Laboratory  evaluations (hematology , clinical chemistry , lipids) 
Pregnancy  and assessment of fertility
Tolerability  of study  treatment 
Other assessments Quality  of Life questionnaires/ Patient reported outcomes 
(PROs)
Data analysisThe primary  endpoint in the study  is the proportion of subjects who 
achieve an ACR20 response at Week 52. The statistical hypothesis 
for ACR20 being tested is that there is no difference in the proportion 
of subjects fulfilling the ACR20 criteria at Week 52 in the 
secukinumab 300 mg group vs. adalimumab.
Let pj denote the proportion of ACR20 responders at Week 52 for 
treatment regimens j, j=0, 1 where 
--0 corresponds to adalimumab,
--1 corresponds to secukinumab 
In statistical terms, H1: p1 = p0, HA1: p1 ≠p0, i.e.
H1: secukinumab is not different to adalimumab regimen for signs 
and sy mptoms (ACR20 response) at Week 52
The primary  endpoint of ACR20 at Week 52 in the FAS will be 
evaluated using a logistic regression with treatment as a factor and 
weight as a covariate. Odds ratios will be computed for comparisons 

Novartis Confidential Page 21
Amended Protocol Version 02 Clean Protocol No. CAIN457F2366
of secukinumab 300 mg vs. adalimumab regimen utilizing the 
logistic regression model fitted. 
Safety  analyses will include summaries of AEs, laboratory 
measurements, and vital signs.
Key wordspsoriatic arthritis, secukinumab, adalimumab, monoclonal antibody, 
CASPAR

Novartis Confidential Page 22
Amended Protocol Version 02 Clean Protocol No. CAIN457F2366
1 Introduction
1.1 Background 
Psoriatic arthritis ( PsA), a chronic inflammatory disease that can affect peripheral and axial 
joints, entheses and the skin, is associated with impaired phy sical function and poor quality  of 
life (Gladman 2005; Rosen 2012 ). Pathogenesis -based interventions, particularl y therapies 
targeting tumour necrosis factor (TNF), have improved outcomes in patients with PsA. Recently, 
the interleukin 12/23 inhibitor ustekinumab has al so shown some clinical benefit but inhibition 
of radiographic progression mainly  in anti-TNF naïve patients ( McInnes 2013; Kavanaugh 
2014). Despite this progress, not all patients respond to or tolerate therapy , and clinical needs 
are largel y unmet. 
Interleukin (IL) 17A and its receptor are expressed in synovial tissues and as such the IL-17 
pathway  is proposed to contribute to the pathogenesis of PsA. IL-17A can mediate a variet y of 
effector biological functions that can result in skin, enthesial joint inflammation, bone damage 
and tissue remodelling ( FitzGerald 2014
). 
Secukinumab, a human monoclona l antibody  that inhibits the effector function of IL-17A, has 
been previousl y shown to be better than placebo, etanercept and ustekinumab in improving the 
signs and s ymptoms of psoriasis ( Langley  2014; Thaci 2015 ). In the phase III, FUTURE 1 and 
FUTURE 2 studies, of 1003 patients with PsA, secukinumab significantl y improved key clinical 
domains of disease versus placebo, including signs and symptoms, radiographic disease 
progression, ph ysical functioning and quality  of life ( Mease 2015 ; McInnes 2015 ). 
Most anti-TNF inhibitors including adalimumab (Humira®package insert ; Humira®SmPC 
2016), as well as secukinumab, an IL-17A inhibitor (Cosenty x®package insert ; Cosenty x®
SmPC 2016), are approved for treatment of patients with active PsA with or without 
methotrexate (MTX). Results on signs and symptoms with both adalimumab and secukinumab 
have demonstrated good re sponse with or without MTX. This suggests that both treatments are 
effective without the need of unwarranted exposure to MTX and its well-recognized toxic effect. 
In fact up to 40% of patients treated with the most commonly  used disease -modify ing anti-
rheumatic drug (DMARD), MTX, discontinue or are noncompliant with MTX because of toxic 
effects ( Nikiphorou 2014
). In addition, data from registries of biological drugs and a US claims 
database suggest that up to a third of patients take TNF inhibitors as monotherap y (Behrens 
2015; Bonafede 2013 ).
It is noteworthy  that the current selection of biological DMARDs to manage PsA is empirical 
(Gossec 2016). As such, a need exists for comparative studies to assess new treatments. This 
study  compares adalimumab and secukinumab as monotherapy , in keeping with approved 
labels, and will provide critical scientific evidence that will improve evidence
-based decision 
making in the treatment of patients with PsA. This study  addresses the current data gap between 
clinical research and day-to-day clinical practice on the therapeutic utility  of biologic 
monotherap y in patients with active PsA.
1.2 Purpose 
The purpose of this study is to compare the safety  and efficacy  of secukinumab monotherap y 
and adalimumab monotherap y in patients with active psoriatic arthritis who are naïve to 

Novartis Confidential Page 23
Amended Protocol Version 02 Clean Protocol No. CAIN457F2366
biologic therapy  for PsA or PSO and are intolerant or having inadequate response to cDMARDs 
(e.g. MTX). Efficacy  will be evaluated based on multiple indices of improvem ent in signs and 
symptoms, phy sical function , quality  of life and patient reported outcomes.
2 Study  objectives and endpoints
2.1 Primary  objective
To demonstrate that the efficacy  of secukinumab monotherap y (300 mg s.c.) at Week 52 is 
superior to adalimumab monotherap y (40 mg s.c.), based on the proportion of subjects 
achieving an American College of Rheumatology  20 (ACR20) response.
2.2 Secondary  objectives
To demonstrate that:
Secukinumab monotherapy  (300 mg s.c.) is superior to adalimumab monotherapy  (40 mg s.c.) 
at Week 52, based on the proportion of subjects achieving PASI90 response.
Secuk inumab monotherapy  (300 mg s.c.) is superior to adalimumab monotherapy  (40 mg s.c.) 
at Week 52, based on the proportion of subjects achieving an ACR50 response.
The improvement (change) from baseline on secukinumab monotherapy  (300 mg s.c.) is 
superior to adalimumab monotherap y (40 mg s.c.) at Week 52, for the Health Assessment 
Questionnaire –Disability  Index (HAQ -DI©) score.
Secukinumab monotherapy  (300 mg s.c.) is superior to adalimumab monotherapy  (40 mg s.c.) 
at Week 52, based on the proportion of subjects achieving the resolution of enthesitis.
An additional secondary objective is to evaluate the safety  and tolerability  of secukinumab 
monotherap y (300 mg s.c.) compared with adalimumab monotherap y (40 mg s.c.) as assessed 
by vital signs, clinical labora tory values, and adverse events monitoring.

Novartis Confidential Page 24
Amended Protocol Version 02 Clean Protocol No. CAIN457F2366
3 Investigational plan
3.1 Stud y design
This is a randomized, double -blind, active control, multicenter, parallel- group trial evaluating 
secukinumab monotherapy  and adalimumab monother apy in approximately  850 subjects with 
active PsA. A screening period of up to 8 weeks before randomization will assess subject 
eligibility  (see Figure 3-1). Efficacy  assessments will occur through Study  Week 52. Two 
follow -up visits at Week 60 and 68 will occur thereafter. Total maximum study  duration, 
including screening period, is up to 76 weeks.
At Baseline (BSL), subjects whose eligibility  is confirmed will be randomized to one of two 
groups (1:1): Group 1 (secukinumab 300 mg) with approximately  425 subjects or Group 2 
(adalimumab 40 mg) with approximately  425 subjects. In order to maintain the blind, both 
groups will receive 1 or 2 placebo s.c. injections to keep consistency  in the number of injection s 
at each dosing visit. Secukinumab (300 mg) is available in 2 x 1.0 mL pre -filled syringes (PFS) 
and adalimumab is available in 1 x 0.4 mL PFS. Placebo (1.0 and 0.5 mL PFS) is also available.
Group 1 - Secukinumab 300 mg s.c.
Secukinumab 300 mg (2 x 1 mL PFS) will be administered at Baseline, Weeks 1, 2, 3 and 4, 
followed b y dosing every 4 weeks until Week 48.
In addition, all Group 1 subjects will receive placebo (1 x 1mL  PFS) at given visits in order to 
maintain the blind (see Figure 3-1; Table 5 -1).
Group 2 
- Adalimumab 40 mg s.c.
Adalimumab 40 mg (1 x 0.4mL  PFS) will be administered at Baseline followed by dosing every 
2 weeks until Week 50. 
In addition, all Group 2 subjects will receive placebo (1 x 0.5mL or 2 x 0.5mL  PFS) at given 
visits in order to maintain the blind (see Figure 3-1; Table 5-1).
Study  staff involved in drug handling and administration (e.g., investigational treatment receipt, 
inventory , storage, administration, and accountability ) and IRT processes, will be unblinded 
and must not be the investigator or study  staff involved in safet y and efficacy  assessments or 
eCRF completion. In addition, investigational treatment administered by the designated study 
staff member who is unblinded to treatment assignment must be done in a manner that maintains 
subject blinding as described in the Study  Reference Manual. All other subject -
related activities 
will be managed b y blinded site personnel throughout the study . 
Rescue medication, defined as any other therapeutic intervention for PsA should be avoided 
before completion of Week 52 assessments (see Section 5.5.6). Although no subject will be 
restricted from receiving necessary  intervention for lack of benefit or worsening of disease, 

Novartis Confidential Page 25
Amended Protocol Version 02 Clean Protocol No. CAIN457F2366
subjects will be discontinued from the investigational treatment if rescued with prohibited 
medications (as described in Section 5.5.8).  Subjects who take rescue medication in the study  
can continue to attend all subsequent scheduled visit assessments unless informed consent is 
withdrawn. 
Figure 3
-1 Study  design
3.2 Rationale for study  design
In PsA, more than half of the patients take biological DMARDs as a monotherapy  with very
good control of their disease (Nikiphorou 2014; Behrens 2015). Similar outcome in response 
has been demonstrated with or without use of the cDMARDs (including MTX). Thus no 
biologics have shown positive sy nergistic effects on any  clinical outcomes and this is reflected 
in all their labels. A strategy  of treatment with biologic monotherap y in PsA is therefore 
clinically  justifiable and avoids unwarrante d exposure to the potential toxicity  of cDMARDs.
The randomized, double -blind, active control, multicenter, parallel -group design used in this 
study  is in alignment with phase III trials of other biologics in this disease area and also in 
compliance with the European Medicines Agency  (EMA) guidelines on PsA trials ( EMA 2005 ). 
3.3 Rationale for dose/regimen, route of administration and duration 
of treatment
The dosing regimens in this study  rely upon dose- efficacy  relationships observed in a PoC trial 
(CAIN457A2206) and two phase III trials (CAIN457F2306, CAIN457F2312) in PsA, as 
described below. The 24-week placebo -controlled PoC trial in 42 patients with PsA 
(CAIN457A2206) showed that two i.v. secukinumab doses of 10 mg/kg given 3 weeks apart 
were well
-tolerated. ACR response endpoints consistently  showed numericall y greater 
responses for secukinumab compared with placebo, up to and including week 24. Post hoc and 
Randomization
Group 1Secukinumab 300 mgGroup 2Adalimumab 40 mg
Notes :
represents treatment administration time points – actual number of injections not depicted
represents placebo administration to maintain blinding Primary 
Endpoint
-8 to BSL        4       8          12         16     20    24         28      32     36         40      44       48         52       60         68        

Novartis Confidential Page 26
Amended Protocol Version 02 Clean Protocol No. CAIN457F2366
subgroup analyses showed differences in signs and symptoms at 6 weeks in TNF -naïve subjects 
(ACR20 response achieved in 62% of subjects receiving secukinumab vs. 20% receiving 
placebo). Posthoc analysis showed that secukinumab, compared with placebo, resulted in 
significant improvement in acute -phase parameters (CRP, ESR) from baseline to Week 6 
(McInnes 2014 ).  
A placebo -controlled, double -blinded phase III study  (FUTURE 1, CAIN457F2306) involving 
606 
patients with active moderate -to-severe PsA used an i.v. loading regimen (3 x 10 mg/kg) 
of secukinumab every  2 weeks followed by secukinumab s.c. 75 mg or 150 mg administered 
every  4 weeks. Secukinumab was well tolerated and produced rapid, clinically  significant and 
sustained improvements in signs and symptoms (i.e. ACR20/50, PASI 75/90), resolution of 
dactylitis and enthesitis and inhibition of joint structural (radiologic) damage at Week 24 in PsA 
patients with or without concomitant MTX (Mease 2015). In a subsequent phase III study 
(FUTURE 2, CAIN457F2312; N=397), secukinumab also resulted in significant improvement 
(compared with placebo) at Week 24 in signs and symptoms of patients with PsA with or 
without concomitant MTX ( McInnes 2015 )
. 
In the PsA phase III studies, secukinumab administered at 300 mg s.c. suggested a potential for 
additional improvement compared to 150 mg in some TNF naïve patients. In accordance with 
the US prescribing information, if patients conti nue to have active PsA, a dosage of 300 mg s.c. 
should be considered (Cosenty x®package insert ). This study  will evaluate secukinumab (300 
mg) for the treatment of adults with active PsA compared with adalimumab (Humira; 40mg 
s.c.). 
Adalimumab is approved for the treatment of PsA at a recommended dose of 40 mg 
administered every  other week, and this is the regimen patients randomized to the adalimumab 
group will receive. For secukinumab, the approved PsA treatments include both the 150 mg and 
300 mg dose regimens (at Weeks 0, 1, 2, 3, and 4 followed b y ever y 4 weeks). 
In summary , the secukinumab maintenance regimen in this study  is based on data suggesting 
optimal efficacy  and safety  in PsA; the dose for the adalimumab active control is based on an 
approved dose from data showing optimal efficacy and safet y in patients with PsA.
Formulation to be used
This study  will use secukinumab 150mg/1mL and placebo liquid, in single -use PFS. 
Adalimumab will be admi nistered in the formulation approved for PsA (40 mg/0.4 mL) in a 
single -use PFS. 

Novartis Confidential Page 27
Amended Protocol Version 02 Clean Protocol No. CAIN457F2366
3.4 Rationale for choice of comparator
An active comparator group is necessary  to evaluate whether secukinumab is superior to an 
approved therapy  in PsA. The parallel- group contr olled design is the most appropriate method 
to compare the two therapies and is consistent with the study of other biologics in the treatment 
of PsA.
In order to demonstrate superiority of secukinumab 300 mg to the standard of care treatment in 
PsA, adalim umab was chosen, being the commonly accepted reference therapy. 
3.5 Purpose and timing of interim analy ses/design adaptations
The primary  analysis may be conducted when all patients complete the Week 52 visit. In the 
case this analysis is conducted, all patie nts will have final data pertaining to the Week 52 
endpoints, thus no adjustment to the type I error will be made and the final analy sis after the 
last visit (Week 68) will include the data collected from the post -treatment follow -up period. 
3.6 Risks and ben efits 
Secukinumab has shown efficacy  in several inflammatory  diseases, including PsA, AS, and 
psoriasis. The large safety  dataset of secukinumab across indications involving over 8,200 
patients did not show unexpected safety  issues relative to the known mode of action. I n general, 
secukinumab is safe and well-tolerated and has demonstrated a similar safet y profile to 
etanercept and ustekinumab in two head -to-head comparison studies over one -year in psoriasis 
(Langley  2014; Thaci 2015 ) . The most frequently  reported AEs are non-serious mild to 
moderate infections, mainly  upper respiratory  tract infections. In addition, there is an increase 
in superficial candidiasis, mainly  oral candidiasis, with secukinumab compared with placebo, 
but the cases were generally mild or moderate in severity , non- serious and responsive to 
standard treatment. There is also a small increase in neutropenia cases with secukinumab 
compared with placebo. Common Toxicity  Criteria (CTC) AE grade 3 neutropenia (<1.0 -
0.5 x 
109/L) was uncommonl y observed with secukinumab, and most cases were mild to moderate, 
transient and reversible and without a temporal relationship to serious infections. 
Hypersensitivity  reactions include urticaria. Rare events of anaphy lactic reaction to 
secukinumab have also been observed in clinical studies. 
With adalimumab (Humira®), the most common adverse reactions (incidence >10%) across 
indications are infecti ons (e.g. upper respiratory , sinusitis), injection site reactions, headache 
and rash (Humira®package insert ; Humira®SmPC 2016). The most serious adverse reactions 
were serious infections including hepa titis B virus reactivation, neurologic or hematological 
reactions, autoimmune disorders and malignancies. In clinical trials of Humira®, allergic 
reactions overall (e.g., allergic rash, anaphy lactoid reaction, fixed drug reaction, non -specified 
drug reacti on, urticaria) were observed in approximately  1% of patients.
The immunogenicity  potential, i.e. of eliciting anti-drug antibodies (ADA), is higher for 
adalimumab (up to 26%) than for secukinumab (<1%) (Humira®package insert ;Cosenty x®
package 
insert ). However, the presence of ADAs does not appear to be associated with 
development of adverse reactions or lack of efficacy  for both secukinumab and adalim umab.

Novartis Confidential Page 28
Amended Protocol Version 02 Clean Protocol No. CAIN457F2366
Taking into account the individual risks as outlined above, the expected risk profile of 
secukinumab from its mechanism of action is anticipated to be similar or improved compared 
to the other approved inflammatory  cytokine -targeting therapies. The risk to subjects in this 
trial will be minimized by compliance with the eligibility  criteria, close clinical monitoring, and 
extensive guidance to the investigators provided by Novartis and in the current version of the 
Investigator Brochure for secukinumab . Based on the overall favorable risk-benefit assessment, 
the current trial with secukinumab (and the comparator adalimumab) is justified.
4 Population
The study  population will consist of a representative group of male or female subjects at least 
18 years of age, fulfilling the Classification criteria for Psoriatic Arthritis (CASPAR) criteria 
(see Appendix 1) and PsA for at least 6 months and have active PsA disease defined as >3 
swollen and tender joints in spite of treatment with NSAI Ds and/or cDMARDs. The goal is to 
randomize approximately  850 subjects. Subjects will be eligible to enter the study  if they  have 
not previously  been treated with biologic DMARDs for PsA or PSO (e.g., TNFα inhibitor), or 
cell-depleting therapies and either, have previously  been treated with cDMARD, including but 
not limited to MTX, with an inadequate response on therapy  or have stopped treatment due to 
safet y/tolerability  problems after at least one administration of a cDMARD .
The study population will be comprised of the subjects who have passed screening assessments 
and who compl y with eligibility  criteria. Subjects can be re-screened only once, and no study 
related re-screening procedures should be performed before re-conse nt by the subject. Mis
-
randomized subjects will not be re- screened.
4.1 Inclusion criteria
Patients eligible for inclusion in this study have to fulfill allof the following criteria:
1.Informed consent must be obtained before an y assessment is performed.
2.Male or non- pregnant, non -lactating female subjects at least 18 y ears of age.
3.Diagnosis of PsA as classified by  CASPAR criteria (see Appendix 1 ) and with sy mptoms
for at least 6 months and with active PsA at baseline defined as ≥3 tender joints out of 78
and ≥3 swollen joints out of 76 (dact ylitis of a digit, counts as one joint each).
4.Rheumatoid factor (RF) and anti -cyclic citrullinated peptide (CCP) antibodies negative at
screening.
5.Diagnosis of active plaque psoriasis, with at least one psoriatic plaque of 
≥2 cm diameter
or nail changes consistent with psoriasis or documented history  of plaque psoriasis.
6. Subjects with PsA should have taken NSAIDs for at least 4 weeks prior to randomization
with inadequa te control of sy mptoms or at least one dose if stopped due to intolerance to
NSAIDs.
7.Subjects who are regularly receiving NSAIDs as part of their PsA therap y are required to
be on a stable dose for at least 2 weeks before study randomization and should rem ain on a
stable dose up to Week 52.
8.Subjects receiving corticosteroids must be on a stable dose of ≤10 mg/day  prednisone or
equivalent for at least 2 weeks before randomization and should remain on a stable dose
up to Week 52.

Novartis Confidential Page 29
Amended Protocol Version 02 Clean Protocol No. CAIN457F2366
9.Subjects must have previously been treated with a cDMARD, including but not limited to 
MTX, with an inadequate response to therap y, or must have stopped treatment due to 
safet y/tolerability  problems after at least one administration of the cDMARD. 
Subjects who are receiving a cDMARD will be allowed to enter the study only after cDMARD 
discontinuation and appropriate wash -out e.g. 4 weeks prior to randomization visit except for 
leflunomide, which has to be discontinued for 8 weeks prior to randomization unless a 
cholesty ramine wash-out has been performed.
4.2 Exclusion criteria
Patients fulfilling any of the following criteria are not eligible for inclusion in this study . No 
additional exclusions may be applied by the investigator, in order to ensure that the study 
population will be repres entative of all eligible subjects.
1.Pregnant or nursing (lactating) women, where pregnancy  is defined as the state of a female 
after conception and until the termination of gestation, confirmed by  a positive human 
chorionic gonadotropin (hCG) laboratory  test.
2.Women of childbearing potential, defined as all women phy siologicall y capable of 
becoming pregnant, unless they  are using effective methods of contraception during 
dosing of stud y treatment and minimum 16 weeks or longer if local label requires it after
the last dose (e.g. 20 weeks for secukinumab, 5 months for adalimumab in EU). Effective 
contraception methods include:
Total abstinence (when this is in line with the preferred and usual lifest yle of the 
subject. Periodic abstinence (e.g., calendar, ovula tion, sy mptothermal, post -ovulation 
methods) and withdrawal are not acceptable methods of contraception.
Female sterilization (have had surgical bilateral oophorectom y with or without 
hysterectom y), total h ysterectom y or tubal ligation at least six weeks b efore taking 
investigational drug. In case of oophorectom y alone, only when the reproductive 
status of the woman has been confirmed b y follow up hormone level assessment.
Male sterilization (at least 6 months prior to screening). For female subjects on the
study , the vasectomized male partner should be the sole partner for that subject.
Barrier methods of contraception: Condom or Occlusive cap (diaphragm or 
cervical/vault caps). For UK: with spermicidal foam/gel/film/cream/vaginal 
suppository . 
Use of oral, (estrogen and progesterone), injected or implanted hormonal methods of 
contraception or other forms of hormonal contraception that have comparable efficacy  
(failure rate <1%), for example hormone vaginal ring or transdermal hormone 
contraception or placem ent of an intrauterine device (IUD) or intrauterine sy stem 
(IUS). In case of use of oral contraception, women should have been stable on the 
same pill for a minimum of 3 months before taking investigational drug .
In case local regulations deviate from the methods listed, local regulations apply  and will be 
described in the ICF.
Women are considered post-menopausal and not of child bearing potential if they have had at 
least 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. 

Novartis Confidential Page 30
Amended Protocol Version 02 Clean Protocol No. CAIN457F2366
age appropriate, history  of vasomotor symptoms) or have had surgical bilateral oophorectomy 
(with or without hysterectomy ), total hysterectomy  or tubal ligation at least six weeks ago. In 
the case of oophorectomy  alone, only when the reproductive status of the woman has been 
confirmed by follow up hormone level assessment is she considered not of child bearing 
potential. 
3.Chest X -ray or chest magnetic resonance imaging (MRI) with evidence of ongoing 
infectious or malignant process obtained within 3 mon ths prior to screening and evaluated 
by a qualified phy sician.
4.Previous exposure to any biologic drugs for PsA and PSO, including but not limited to 
TNFα inhibitors, secukinumab or other biologic drugs targeting IL-17 or IL-17 receptor.
5.Subjects receiving high-potency  opioid analgesics, including but not limited to , 
methadone, h ydromorphone, and morphine.
6. Ongoing use of prohibited psoriasis treatments/medications (e.g., topical corticosteroids or 
ultraviolet (UV) therap y at randomization). The following wa sh out periods need to be 
observed:
Oral or topical retinoids: 4 weeks.
Photochemotherap y (e.g., PUVA): 4 weeks.
Phototherapy  (UVA or UVB): 2 weeks.
Topical skin treatments (except in face, ey es, scalp and genital area during screening; 
only corticosteroids with mild to moderate potency ): 2 weeks.
7. Previous treatment with any  cell-depleting therapies, including but not limited to anti -
CD20 or investigational agents (e.g., alemtuzumab (Campath®), anti -CD4, anti -CD5, anti -
CD3, and anti -CD19).
8. Use of other inve stigational drugs within 5 half -lives of enrollment, or within 30 day s until 
the expected pharmacodynamic effect has returned to baseline, whichever is longer.
9.History  of hypersensitivity  to any  of the study  drugs or excipients or to drugs of similar 
chemi cal classes.
10.Any intramuscular or intravenous corticosteroid treatment within 4 weeks before 
randomization.
11.Any therapy  by intra -articular injections (e.g., corticosteroid) within 4 weeks before 
randomization.
12.Active ongoing inflammatory  diseases other tha n PsA that might confound the evaluation 
of the benefit of secukinumab therap y.
13.Underl ying metabolic, hematologic, renal, hepatic, pulmonary , neurologic, endocrine, 
cardiac, infectious or gastrointestinal conditions which in the opinion of the investigator
immunocompromises the subject and/or places the subject at unacceptable risk for 
participation in an immunomodulatory  therapy .
14.Significant medical problems or diseases, including but not limited to the following: 
uncontrolled hy pertension ( ≥160/95 mmHg), congestive heart failure (New York Heart 
Association status of class III or IV) and uncontrolled diabetes.
15.History  of clinically  significant liver disease or liver injury  as indicated b y abnormal liver 
function tests (LFTs) such as aspartate aminotransfera se/serum glutamic oxaloacetic 
transaminase (AST/SGOT), alanine aminotransferase/ serum glutamic p yruvic 

Novartis Confidential Page 31
Amended Protocol Version 02 Clean Protocol No. CAIN457F2366
transaminase (ALT/SGPT), alkaline phosphatase or serum bilirubin. The investigator 
should be guided b y the following criteria:
a.Any single parameter may  not exceed 2 x upper limit of normal (ULN). A single 
parameter elevated up to and including 2 x ULN should be re- checked once more as 
soon as possible and in all cases, at least prior to enrollment/randomization, to rule 
out any  possible lab error.
b.If the total bilirubin concentration is increased above 2 x UL N, total bilirubin should 
be differentiated into the direct and indirect reacting bilirubin. 
16.History  of renal trauma, glomerulonephritis, or subjects with one kidney  only , or a serum 
creatinine level exceeding 1.5 mg/dL (132.6 µmol/L ).
17.Screening total white blood cell (WBC) count <3,000/µL , or platelets <100,000/µL  or 
neutrophils <1,500/µL  or hemoglobin <8.5 g/dL (85 g/L).
18.Active sy stemic infections during the last two weeks (exception: common cold) pr ior to 
randomization.
19.History  of ongoing, chronic or recurrent infectious disease or evidence of tuberculosis 
infection as defined b y either a positive purified protein derivative (PPD) skin test (the 
size of induration will be measured after 48 -72 hours, and a positive result is defined as an 
induration of ≥ 5mm or according to local practice/guidelines), or a positive 
QuantiFERON TB- Gold test. Subjects with a positive test may  participate in the study  if 
further work up (according to local practice/guidel ines) establishes conclusively  that the 
subject has no evidence of active tuberculosis. If presence of latent tuberculosis is 
established then treatment according to local country guidelines must have been initiated 
prior to enrollment.
20.Known infection wit h human immunodeficiency  virus (HIV), hepatitis B or hepatitis C at 
screening or randomization.
21.History  of lymphoproliferative disease or an y known malignancy  or history  of malignancy  
of an y organ s ystem within the past 5 y ears (except for basal cell carci noma or actinic 
keratoses that have been treated with no evidence of recurrence in the past 3 months, 
carcinoma in situ of the cervix or non -invasive malignant colon pol yps that have been 
removed).
22. Current severe progressive or uncontrolled disease which i n the judgment of the clinical 
investigator renders the subject unsuitable for the trial.
23.Inability  or unwillingness to undergo repeated venipuncture (e.g., because of poor 
tolerability  or lack of access to veins).
24.Any medical or ps ychiatric condition which, in the investigator’s opinion, would preclude 
the participant from adhering to the protocol or completing the study  per protocol.
25.Donation or loss of 400 mL  or more of blood within 8 weeks before randomization.
26.History  or evidence of ongoing alcohol or drug abuse, within the last six months before 
randomization.
27.Plans for administration of live vaccines during the study  period or within 6 weeks 
preceding randomization.

Novartis Confidential Page 32
Amended Protocol Version 02 Clean Protocol No. CAIN457F2366
5 Treatment
5.1 Stud y treatment
5.1.1 Investigational and control drugs
Novartis will supply  the following study  drugs:
Investigational treatment
--Secukinumab 150 mg, liquid formulation in 1 mL PFS (2 x 1 mL  PFS for 300 mg dose)
Reference treatment
--
Placebo, liquid formulation in a 1 and 0.5 mL  PFS
--Adalimumab 40 mg, liquid formulation in a 0. 4 mL  PFS
The study  drugs will be administered by a designated study  staff member at the site, who will 
be unblinded to treatment assignment (secukinumab vs. adalimumab), in a manner that 
maintains subject blinding and as described in the Study  Reference Manual. The individual 
administering the investigational treatment must not be the investigator or study  staff involved 
in safet y and efficacy  assessments or eCRF completion. The injections through Week 50 will 
be performed at the study site. Site staff and patient may  agree on home administration at some 
visits as per Table 6-1 (Assessment schedule).
Secukinumab 150mg PFS and placebo 1 mL PFS will be provided in a double blind fashion 
and have identical appearance.
Adalimumab 40mg PFS and placebo 0.5 mL PFS will be provided as open label supplies. They 
have different appearance from each other and from secukinumab 150mg/placebo 1mL.
All study  drugs will be labeled accordingl y. 
For detailed instructions on s torage of the stud y drugs, please refer to Section 5.5.3 .
5.1.2 Additional treatment
No additional treatment beyond investigational and reference treatments are included in this 
trial.
5.2 Treatment arms
Subjects will be randomly  assigned to one of two treatment 
Groups in a 1:1 ratio, with 
approximately  425 subjects planned for each group. Subjects in Group 1 will receive 
secukinumab 300 mg, subjects in Group 2 will receive adalimumab 40 mg. 
Group 1: 
--secukinumab 300 mg s.c.: 2 x 1.0 mL  PFS (150 mg)
Group 2: 
--adalimumab 40 mg s.c.: 0.4 mL  PFS (40 mg)
In order to maintain the blind, both groups will receive the same number of s.c. injections of 
active and/or placebo at each dosing visit throughout the study , as follows:

Novartis Confidential Page 33
Amended Protocol Version 02 Clean Protocol No. CAIN457F2366
If the subject is allocated to Group 1, they will receive secukinumab 300 mg as two PFS, or one 
placebo 1mL PFS at specified visits as shown in Table 5-1 below.
If the subject is allocated to Gro up 2, they  will receive adalimumab 40 mg as one PFS, or one 
adalimumab PFS and one placebo 0.5mL PFS, or two placebo 0.5mL PFS at specified visits as 
shown in Table 5-1 below.
Table 5-1 Blinding scheme
Study dosing visits (in weeks, from randomization)
Treat ment assignment/ 
study drug 
administration
0
1
2
3
4
6
8
10
12
14
16
18
20
22
24
26
28
30
32
34
36
38
40
42
44
46
48
50
52Group 1
secukinumab 
300mgsecukinumab 
300mg
1ml PFS2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
Placebo
1ml PFS 1 1 1 1 1 1 1 1 1 1 1 1Group 2
adalimumab
40mgadalimumab
40mg
0.4ml PFS1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Placebo 
0.5ml PFS 1 2 1 2 1 1 1 1 1 1 1 1 1 1 1 1
Site staff and patient may agree on home administration at some visits as per Table 6-1
(Assessment schedule).
5.3 Treatment assignment and randomization 
At baseline, all eligible subjects will be randomized via I RT to one of the two treatment groups 
(secukinumab 300 mg s.c. or adalimumab 40 mg s.c.) as described
 in Section 5.2. A designated 
site staff member other than the investigator or study  staff involved in safet y and efficacy 
assessmen ts or eCRF completion will contact IRT after confirming that the subject fulfills all 
the inclusion/exclusion criteria. The IRT will assign a randomization number to the subject, 
which will be used to link the subject to a treatment arm and will specify  a unique medication 
number for the first package of investigational treatment to be dispensed to the subject. The 
randomization number will not be communicated to the investigator or study site staff involved 
in the conduct of efficacy assessments. 
The randomization numbers will be generated using the following procedure to ensure that 
treatment assignment is unbiased and concealed from subjects and study staff (except for those 
involved in drug handling, drug administration, and IRT processes): a subject randomization 
list will be produced by the IRT provider using a validated system that automates the random 
assignment of subject numbers to randomization numbers. These randomization numbers are 
linked to the different treatment arms, 
which in turn are linked to medication numbers. A 
separate medication list will be produced by or under the responsibility  of Novartis Drug Supply 
Management using a validated system that automates the random assignment of medication 
numbers to packs containing the stud ydrug(s). 

Novartis Confidential Page 34
Amended Protocol Version 02 Clean Protocol No. CAIN457F2366
The randomization scheme for subjects will be reviewed and approved by a m ember of the 
Randomization Group. 
5.4 Treatment blinding
This is a double -blind randomized treatment trial. 
Subjects, investigators, site personnel, and persons performing the assessments (except for 
those described below) will remain blinded to treatment assignment from the time of 
randomization until the database lock and analy ses are completed, using the following methods:
Randomization data are kept strictly  confidential until the time of unblinding and will not be 
accessible by  anyone else involved in the study  with the exception of the bioanaly st.
Investigational treatment will be dispensed by an unblinded pharmacist (or other unblinded 
qualified site personnel) who is independent of those involved in the assessment of study 
subjects. I n addition the unblinded pharmacist (or other unblinded qualified site personnel) will 
store study  medication and keep medication records containing unblinded information in a 
separate area to which blinded staff do not have access.
Study  treatments will be administered by “independent study  drug administrator” -an unblinded 
suitably  qualified individual (nurse, physician, or other unblinded qualified site personnel) who 
is not responsible for any aspect of subject assessment or follow -up. “Independent study  drug 
administrator” could be the same person dispensing the drug if suitabl y qualified to perform 
both activities. 
Prior to the administration, the unblinded site personnel will put in p lace suitable methods, e.g 
physical barriers such as curtains, blindfolds, or similar as agreed with the subject and available 
to prevent subject seeing the appearance of their study  treatment and keep the blind. The 
procedural details relating to treatment blinding and blinded drug administration will be 
described in the Stud y Reference Manual which will be provided separately.
The individual administering study  treatment and all study  subjects will be advised to refrain 
from making any comments to study  staff or to other subjects regarding the appearance of study 
treatments 
Unblinding will occur in the case of subject emergencies (see Section 5.5.12) and at the 
conclusion of the study . The appropriate s tudy site and Novartis personnel will assess whether 
the study  treatment should be discontinued for any subject whose treatment code has been 
broken inadvertently  for any  reason.
The high sensitivity  C-reactive protein (hsCRP) results from samples collected during the 
treatment period will be revealed onl y after database lock and analy ses are completed.

Novartis Confidential Page 35
Amended Protocol Version 02 Clean Protocol No. CAIN457F2366
5.5 Treating the subject 
5.5.1 Subject numbering
Each subject is uniquel y identified b y a Subject Number which is composed by the site number 
assigned b y Novartis and a sequential number assigned by  the investigator. Once assigned to a 
subject, the Subject Number will not be reused. 
Upon signing the inf ormed consent form, the subject is assigned the next sequential number b y 
the investigator. Study  personnel other than the investigator or study staff involved in safety 
and efficacy  assessments  will contact the IRT and provide the requested identify ing 
information for the subject to register them in the IRT. The site should select the electronic case 
report form (eCRF) book with the matching Subject Number from the electronic data capture 
(EDC) s ystem to enter data. 
If the subject fails to be treated for any reason, the IRT must be notified within 2 day s that the 
subject was not treated. The reason for not being treated will be entered on the Screening Stud y 
Disposition CRF.
Subjects may  be re -screened once and will receive a new Subject Number after they have been 
re-consented. Subjects who are mis -randomized cannot be re -screened.
5.5.2 Dispensing the investigational treatment 
Each study  site will be supplied by Novartis with secukinumab 150mg/1 mL PFS and 1 mL 
placebo PFS in packaging of identical appearance . Novartis will also suppl y adalimumab 40mg 
/0.4 mL  PFS and 0.5 mL placebo PFS as open label supplies.
The investigational treatment packaging has a 2-part label. A unique medication number is 
printed on each part of this label which corresponds to placebo or active treatment.  The 
unblinded pharmacist (or other unblinded qualified site personnel) will identify  the 
investigational treatment package(s) to dispense to the “independent study  drug administrator” -
by contacting the IRT and obtaining the medicati on number(s) -. Immediately before dispensing 
the package to the “independent study  drug administrator”, the unblinded pharmacist will 
detach the outer part of the label from the packaging and affix it to the source document (Drug 
Label Form) for that subje ct’s unique subject number. 
5.5.3 Handling of study  treatment 
5.5.3.1 Handling of investigational treatment 
Study  Investigational treatment must be received by a designated unblinded site staff member 
at the study  site, handled and stored safel y and properly , and kept in a secured location to which 
only the unblinded site personnel have access. Upon receipt, all investigational treatment should 
be stored according to the instructions specified on the labels. Clinical supplies are to be 
dispensed only  in accordance wit h the protocol. Technical complaints are to be reported to the 
respective Novartis Country  Pharma Organization Quality  Assurance (CPO QA).

Novartis Confidential Page 36
Amended Protocol Version 02 Clean Protocol No. CAIN457F2366
Medication labels will be in the local language and comply with the legal requirements of each 
country . They  will inc lude storage conditions for the study  treatment but no information about 
the subject except for the medication number.
Single PFS will be packaged in individual boxes. The PFS sealed in its outer box must be stored 
in an access controlled/locked refrigerat or. They must be carefull y controlled in accordance 
with applicable regulations governing investigational medicinal products and the active 
reference therap y (adalimumab).
The pharmacist or other qualified site personnel must maintain an accurate record ofthe 
shipment and dispensing of study treatment in a drug accountability log which will be kept in a 
Pharmacy  File in a secured location to which no blinded site staff would have access to. 
Monitoring of drug accountability  will be performed by an unblinde d field monitor (who is not 
the monitor accountable for other portions of the study) during site visits and at the completion 
of the trial. 
At the conclusion of the study  and as appropriate during the course of the study , the investigator 
will return all partly  used and unused investigational treatment, packaging, drug labels and a 
copy  of the completed drug accountabilit y log to Novartis as instructed.
Destruction of unused drug should be done according to local requirements and after approval 
by the Nov artis Clinical Team.
5.5.3.2 Handling of other study  treatment 
Not applicable.
5.5.4 Instructions for prescribing and taking study treatment 
Study  treatments (secukinumab 300 mg, adalimumab 40 mg and placebo) will be administered 
by s.c. PFS throughout the study . Admi nistration of study  treatment must occur only after the 
study  assessments for the visit have been completed. 
Administration of study  treatment will occur at the study  site through Week 50. Site staff and 
patient may agree on home administration by  designa ted site staff at some visits as per Table 6 -
1(Assessment Schedule), in which case the applicable study  assessments can be made by phone 
before stud y treatment administration.
The first study  treatment administration will occur at the baseline/randomization visit only after 
eligibility  criteria have 
been confirmed, all study baseline assessments have been performed 
and the scheduled blood samples have been drawn. At each subsequent visit, all study  
assess ments (as applicable per Table 6-1), should be completed prior to the injection of study  
treatment.  
All investigational treatment kits assigned by the IRT will be recorded in the IRT. The 
investigator should promote compliance by instructing the subject to attend the study  visits as 
scheduled and by stating that compliance is necessary  for the 
subject’s safety  and the validit y 
of the study . The subject should be instructed to contact the investigator if he/she i s unable for 
any reason to attend a study  visit as scheduled.

Novartis Confidential Page 37
Amended Protocol Version 02 Clean Protocol No. CAIN457F2366
5.5.4.1 Subcutaneous administration with PFSs
Secukinumab solution for s.c. injection (150 mg in 1.0 mL active/placebo), adalimumab 
solution for s.c. injection (40 mg in 0.4 mL) and placebo (0.5 mL), will be provided in PFS. 
The study  treatment solution must be injected into non -affected areas of the skin.
The injections will be administered into the appropriate site of the body  (thighs, arms, abdomen) 
and each injection should be given at a different injection site to reduce the risk of reaction. 
Each new injection should be given at least one inch from the previously  used site. If the 
abdomen is chosen, a 2-inch area around the navel should be avoided. Investigational drug 
should not be injected into areas where the skin is tender, bruised, red or hard, or where the 
subject has scars or stretch marks.
Single PFS will be packaged in individual boxes for secukinumab, placebo and adalimumab. 
Prior to administration the boxes containing the PFS with study  treatment solution should be 
allowed to come to room temperature unopened for 15 to 30 minutes prior toinjection. Used 
PFS should be disposed immediately  after use in a sharps container OR according to local 
regulations.
Any PFS for which a defect or malfunction is noticed prior to or during the injection at any  of 
the study  visits must be kept at the siteuntil guidance is received from Novartis on whether it 
should be returned to Novartis for investigation or discarded. Devices identified as defective 
should be stored according to local guidelines, until specific instruction is discussed with 
Novartis personnel. Additionally , from baseline onwards, any noticed defect, malfunction, 
problem during the injections or product complaints with the PFS should be recorded in the 
source document and the Use of Device electronic case report form (eCRF). Sites should detail 
the issue, the date, the kit number and the visit number. Site will be asked to record based on 
their judgment whether the observed issue was primarily  related to the device or to the user. 
Device malfunctions should also be reported to Novartis personnel immediately , as a 
replacement kit may  need to be provided.
5.5.5 Permitted dose adjustments and interruptions of study  treatment 
Investigational treatment dose adjustments are not permitted. For subjects who are unable to 
tolerate the protocol -specified dosing scheme (including subjects who in the opinion of the 
investigator are at significant safet y risk unless dosing is temporarily  interrupted), 
investigational treatment interruption is permitted in order to keep the subject on study drug. In 
such cases , investigational treatment should be interrupted only during the time that a risk is 
present and ongoing. Investigational treatment can be restarted at the next scheduled visit after 
resolution of the safet y risk.
The effect of secukinumab or adalimumab o n live vaccines is unknown; therefore live vaccines 
should not be administered during participation in the study . The elimination of adalimumab 
may take up to four months (Humira®SmPC 2016 );in case a live vaccine has been administered 
due to a medical urgency, study  treatment should be interrupted for four months. 
Any investigational treatment interruption must be recorded on the corresponding eCRF.

Novartis Confidential Page 38
Amended Protocol Version 02 Clean Protocol No. CAIN457F2366
5.5.6 Rescue medication
Rescue medication is defined as anynew therapeutic intervention or a significant change to 
ongoing therap y made because a subject is experiencing either no benefit from participation in 
the trial or worsening/exacerbation of their disease.
Rescue medication must not be used before completi on of Week 52 assessments (see Section 
3.1). Please see Section 5.5.7 and Section 5.5.8 for details. Although no subject will be restricted 
from receiving necessary  rescue medications for lack of benefit or worsening of disease, 
subjects will be discontinued from investigational treatment if treated with prohibited 
medications (as described in Section 
5.5.8). Subjects who discontinue investigational treatment 
can continue to attend all subsequent scheduled visit assessments unless informed consent is 
withdrawn. If study  investigational treatment is discontinued, subjects may take study 
prohibited medication under the investigator’s guidance and per locall y approved prescribing 
information.
Efficacy  and safet y will be assessed in detail at every  study  visit and subjects who are deemed 
by the investigator not to be ben efiting from stud y treatment, or for an y reason on the subject’s 
own accord, will be free to discontinue study  participation at any  time.
Use of rescue medication must be recorded on the corresponding eCRF.
5.5.7 Concomitant medication 
The investigator should i nstruct the subject to notify  the study  site about any  new medications 
over-the-counter drugs, supplements, and vitamins) administered after the subject is enrolled 
into the study . All medications (other than study treatment), procedures and significant non-
drug therapies (including physical therapy  and blood transfusions) must be recorded on the Prior 
and Concomitant medications or Procedures 
and Significant Non Drug Therap y eCRF. The 
reason, name of the drug, procedure or non -drug therapy  should be listed . 
Guidelines for the use of specific medications are provided below.
Leflunomide wash -out w ith cholesty ramine
In case of leflunomide treatment before stud y randomization, a drug wash -out of 8 weeks must 
be performed. However, another wash -out procedure can be considered. Cholesty ramine may 
be given orally at a dose of 8 g three times daily (t.i.d) to wash -out leflunomide. Cholesty ramine 
reduced plasma levels of the active leflunomide metabolite by  approximately  40% in 24 hours 
and by 49% to 65% in 48 hours , in three healthy  volunteers. The administration of 
cholesty ramine is recommended in subjects who require a drug elimination procedure. If a 
subject receives 8 g t.i.d. for 11 days, the subject can be safely  randomized 4 weeks after the 
beginning of the 11- day treatment period. 
Systemic corticosteroids
Treatment with systemic corticosteroids is permitted up to a maximum daily dosage of 10 mg 
prednisone equivalent and if the dose was stable within the 2 weeks preceding randomization. 
The subject should remain on a stable dose until Week 52.

Novartis Confidential Page 39
Amended Protocol Version 02 Clean Protocol No. CAIN457F2366
Corticosteroid dose reductions below 10 mg prednisone equivalent are permitted after Week 52, 
only due to adverse events.
However, any change in the dose of oral corticosteroids during the trial should be recorded on
the corresponding eCRF.
Intra -articular corticosteroids are not permitted within 4 weeks prior to baseline and up to week 
24. After week 24, no more than 1 joint per 24-week period may be injected. No single injection 
should exceed 40 mg of triamcinolone (or equivalent) and the total dose of intra-articular 
corticosteroid may not exceed 80 mg of triamcinolone (or equivalent) during any 52-week 
period. Injection of intra-articular corticosteroids is not permitted within 8 weeks prior to Week 
52. The joints injected with intra -articular corticosteroids will be assessed as both swollen and 
tender in the SJC and TJC, from injection time onwards. 
Non
-steroidal anti -inflammatory  drugs (NSA IDs) (including selective COX -2 
inhibitors), low strength opioids and acetaminophen/paracetamol
Subjects on regular use of NSAIDs or paracetamol/acetaminophen should be on stable dose for 
at least 2 weeks before randomization to allow inclusion.  
Subjects taking NSAIDs, low strength opioids, or paracetamol/acetaminophen PRN within the 
2 weeks before randomization can continue to do so after randomization, however, they have 
to refrain from any intake during at least 24 hours before a visit with disease activity  assessment.
After Week 52, a change in the NSAI Ds, low strength opioids or paracetamol/acetaminophen 
treatment regimen is permitted.
Any change of the NSAIDs, low strength opioids or paracetamol/acetaminophen treatment 
during the trial should be recorded on the corresponding eCRF.
5.5.8 Prohibited medication
Use of the treatments display ed in Table 5-2is NOT allowed after the start of the washout 
period unless specified otherwise below or in Section 5.5.9.
Live vaccines sh ould not be given until 4 months after last study  treatment administration (see 
Section 5.5.5 ).
Table 5-2 Prohibited medic ation
Medication Action
(after randomization)Washout period
(before randomization)
Any biologic drugs, including but not 
limited to TNFα inhibitors, 
secukinumab, or other biologic drugs 
targeting IL-17 or IL-17 receptorDiscontinue 
investigational 
treatmentBiologics for PsA and 
PSO: never
Biologics for other 
indications: 16 weeks 
Any cell-depleting therapies including 
but not limited to anti -CD20 or 
investigational agents [e.g., Discontinue 
investigational 
treatment Never

Novartis Confidential Page 40
Amended Protocol Version 02 Clean Protocol No. CAIN457F2366
Medication Action
(after randomization)Washout period
(before randomization)
alemtuzumab (Campath), anti -CD4, 
anti-CD5, anti -CD3, and anti -CD19]
cDMARDs (e.g. MTX) including 
apremilast Discontinue 
investigational 
treatment4 weeks
Leflunomide Discontinue 
investigational 
treatment8 weeks
Leflunomide with cholesty ramine 
washoutDiscontinue 
investigational 
treatment4 weeks
Any investigational treatment or 
participation in an y interventional trialDiscontinue 
investigational 
treatment4 weeks or 5 half-lives 
(whichever is longer)
Unstable dose of NSAIDs (selective 
COX -2 inhibitors)Discontinuation of 
investigational 
treatment may  be 
required on a case b y 
case basis. (Dose 
adjustments allowed 
after week 52)2 weeks
Analgesics other than NSAIDs, 
paracetamol/acetaminophen, and low 
strength opioids PRN Discontinue 
investigational 
treatment2 weeks
Systemic corticosteroids > 10 mg 
prednisone equivalent (until Week 52)*If administered due to a 
medical urgency  
unrelated to the 
patient’s arthritis, study  
treatment should 
beinterrupted until the 
steroid is discontinued. 
If administered no t for a 
medical urgency  or 
related to the patient’s 
arthritis, then 
discontinuation of 
investigational 
treatment may  be 
required on a case b y 
case basis2 weeks

Novartis Confidential Page 41
Amended Protocol Version 02 Clean Protocol No. CAIN457F2366
Medication Action
(after randomization)Washout period
(before randomization)
Unstable dose of s ystemic 
corticosteroids ≤ 10 mg prednisone 
equivalent (until Week 52)*Disco ntinuation of 
investigational 
treatment may  be 
required on a case b y 
case basis. (Dose 
adjustments allowed 
after week 52)2 weeks
Intra -articular corticosteroids 
injections, (until Week 52)*Discontinue 
investigational 
treatment, (see Section 
5.5.7)4 weeks
Intramuscular or intravenous 
corticosteroid treatment Discontinuation of 
investigational 
treatment may  be 
required on a case b y 
case basis4 weeks
Live vaccinations If administered due to a 
medical urgency , study  
treatment should be 
interrupted for 4 
months. I f administered 
not for a medical 
urgency  then 
discontinue 
investigational 
treatment 6 weeks
Oral or topical retinoids Discontinue 
investigational 
treatment4 weeks
Photochemotherap y (e.g. PUVA) Discontinue 
investigational 
treatment4 weeks
Phototherapy  (UVA or UVB) Discontinue 
investigational 
treatment2 weeks
Topical skin treatments (except in face, 
eyes, scalp and genital area;  only  
corticosteroids with mild to 
moderate 
potency )Discontinue 
investigational 
treatment2 weeks

Novartis Confidential Page 42
Amended Protocol Version 02 Clean Protocol No. CAIN457F2366
Medication Action
(after randomization)Washout period
(before randomization)
* see details about corticosteroid management in Section 5.5.7
5.5.9 Discontinuation of study treatment
Subjects may voluntarily discontinue study  treatment or the study  for any reason at any time. 
The investigator should discontinue study  treatment for a subject if, on balance, he/she believes 
that continuation would be detrimental to that subject’s well -being.
Study  treatment must be disconti nued under the following circumstances:
Withdrawal of informed consent
Subject’s request to terminate treatment
Emergence of the following AEs:
1.Any severe or serious AE  that requires treatment with an unacceptable co -medication
2.Onset of lymphoproliferative disease or an y malignancy  except for treated basal cell 
carcinoma, treated actinic keratosis, treated in situ carcinoma of the cervix, or non -
invasive malignant colon poly ps which are being or have been removed
3.Life-threatening infecti on
Severe h ypersensitivity  reaction or anaph ylactic reaction
Any laboratory  abnormalities that in the judgment of the investigator are clinically  
significant and are deemed to place the subject at a safet y risk for continuation in the study  
(a general guid ance on clinically  notable laboratory  values is provided in Appendix 7 )
Pregnancy
Use of prohibited treatment as per Table 5 -2and in particular addition of concomitant 
cDMARD (e.g. MTX). Subjects who discontinue study  treatment but continue to attend 
scheduled visits may  use prohibited medications under the guidance of the study  
Investigator.
Any other protocol deviation that results in a significant r isk to the subject’s safety
In addition to these requirements for study  treatment discontinuation, the investigator should 
discontinue study  treatment for a given subject if there is a lack of improvement or worsening 
of their symptoms, or if on balance, the investigator believes that continuation would be 
detrimental to the subject’s well- being.
For subjects who discontinue study  treatment, a Dosage Administration Record eCRF should 
be completed, giving the date and primary  reason for stopping study  treatm ent.
The appropriate personnel from the site and Novartis will assess whether study  treatment should 
be discontinued for any subject whose treatment code has been broken inadvertentl y for any 
reason.
Subjects who discontinue study treatment should NOT be considered withdrawn from the 
study  and can continue to attend all subsequent scheduled visit assessments, except if informed 
consent is withdrawn. 

Novartis Confidential Page 43
Amended Protocol Version 02 Clean Protocol No. CAIN457F2366
5.5.10 Withdrawal of consent
Subjects may be considered discontinued if they state an intention to withdraw, fail to return 
for visits, or become lost to follow -up for an y other reason.
If premature discontinuation occurs for any reason, the investigator must make every  effort to 
determine the primary  reason for a subject’s premature discontinuation from the study  and 
record this information on the appropriate Study  Phase Completion eCRF. Subjects may 
voluntarily  withdraw consent to participate in the study  for any  reason at any  time.
Withdrawal of consent occurs when a subject does not want to participate in the study  anymore, 
that is, the subject does not want any further visits, assessments, or study -related contact and 
does not allow anal ysis of alread y obtained biologic material.
If a subject withdraws consent, the investigator must make every  effort to determine the primary  
reason for this decision and record this information in the Withdrawal of Consent eCRF. Stud y
treatment must be discontinued and no further assessments conducted. All biological material 
that has not been analyzed at the time of withdrawal must not be used. Further attempts to 
contact the 
subject are not allowed unless safet y findings require communicating or follow -up. 
The data collected on the subject to the point of withdrawal remains part of the study  database 
and may  not be removed.
5.5.11 Loss to f ollow -up
For subjects whose status is unclear because they  fail to appear for study  visits without stating 
an intention to withdraw, the investigator should show "due diligence" by contacting the subject, 
family  or famil y physician as agreed in the informe d consent and b y documenting in the source 
documents steps taken to contact the subject, e.g. dates of telephone calls, registered letters, etc. 
A subject should not be formally  considered lost to follow -up until his/her scheduled End-of-
Study  visit would have occurred.
5.5.12 Emergency  breaking of assigned treatment code
Emergency  code breaks should only be undertaken when it is essential to treat the subject safel y 
and efficaciously . Most often, study  discontinuation and knowledge of the possible treatment 
assignments are sufficient to treat a study  subject who presents with an emergency  condition. 
Emergency  treatment code breaks are performed using the IRT. When the investigator contacts 
the system to break a treatment code for a subject, he/she must provide the requested subject 
identify ing information and confirm the necessity to break the treatment code for the subject. 
The investigator will then receive details of the investigational drug treatment for the specified 
subject and a fax or email confirming thisinformation. The system will automatically  inform 
the Novartis monitor for the site and the Global Trial Lead or designee that the code has been 
broken.
It is the investigator’s responsibility  to ensure that there is a dependable procedure in place to 
allow access to the IRT/code break cards at any time in case of emergency . The investigator 
will provide:
protocol number
study  drug name (if available)

Novartis Confidential Page 44
Amended Protocol Version 02 Clean Protocol No. CAIN457F2366
patient number
In addition, oral and written information to the subject must be provided on how to contact 
his/her backup in cases of emergency, or when he/she is unavailable, to ensure that un -blinding 
can be performed at an y time. 
Study  drug must be discontinued after emergency  unblinding.
5.5.13 Study completion and post- study treatment 
A subject will be considered to have completed the study  when the subject has completed the 
last visit planned in the protocol..
Information on the subject’s completion or discontinuation ofthe study and the reason for 
discontinuation of the study  will be recorded on the appropriate Study  Phase Completion eCRF.
In an y case, the investigator or site staff must contact the I RT as soon as possible to record the 
subject’s study completion and/or discontinuation.
The investigator must provide follow -up medical care for all subjects who are prematurel y 
withdrawn from the study , or must refer them for appropriate ongoing care. This care may 
include initiating another treatment outside of the study  as deemed appropriate by the 
investigator. This treatment may be an y non -biologic DMARD. In case of a biologic treatment, 
a waiting period of 4 months before initiating the treatment is recommended; elimination of 
adalimumab may  take up to four months ( Humira®SmPC 2016 ).
5.5.14 Early  study termination 
The study  can be terminated at any  time for any  reason by  Novartis. Should this be necessary, 
the subject must be seen as soon as possible and treated as a premat urely withdrawn subject. 
The investigator may be informed of additional procedures to be followed in order to ensure 
that adequate consideration is given to the protection of the subject’s interests. The investigator 
will be responsible for informing the I nstitutional Review Board (I RBs) or Independent Ethics 
Committee (I ECs) of the earl y termination of the trial.
6 Visit schedule and assessments
Table 6-1lists all of the assessments and indicates with an “x” when the visits (or telephone 
calls) are performed.
Upon agreement between the site and the subject, drug administration at certain visits (as 
specified in Table 6-1can be performed at the subject’s domicile by the independent drug 
administrator. In such cases, concomitant medication/non -drug therap y and Adverse 
Events/SAEs will be collected b y a telephone call.
During the period of the study from Screening to Week 68, the assessments must be performed
as indicated in Table 6 -1. 
Subjects should be seen for all visits on the designated day or as closely  as possible to the 
original planned visit schedule. Missed or rescheduled visits should not lead to automatic 
discontinuation. 

Novartis Confidential Page 45
Amended Protocol Version 02 Clean Protocol No. CAIN457F2366
Subjects who discontinue study  treatment before completing the study  can continue to attend 
all subsequent scheduled visits and perform all assessments except receiving study  treatment, 
unless informed consent is withdrawn. Subjects who prematurel y discontinue from the study
should undergo an End-of- Study  visit (corresponding to the Week 52 visit; see Table 6-1), 4 
weeks after last study  treatment and follow -up visits at 12 week s and 18 weeks after last study 
treatment (assessments as listed for Week 60 and Week 68). The investigator must also contact 
IRT to register the subject’s discontinuation from study  treatment. 
If subjects refuse to return for these assessments or are una ble to do so, every  effort should be 
made to contact them or a knowledgeable informant by telephone to determine the reason. 
Attempts to contact the subject should be recorded in the source documentation.
Screening will be flexible in duration based on thetime required to wash out prior anti-
rheumatic medications and have a duration of up to 8 weeks before randomization, during which 
time the subject will sign the informed consent form (ICF), be evaluated for eligibility , and 
allowed sufficient time for medication washout, if required (see Table 5-2), in addition to all 
other assessments indicated in Table 6
-1.
If subjects do not have a chest X-ray or chest MRI  obtained within 3 months preceding the 
screening visit, a chest X -ray should be performed. I n order to minimize unnecessary  exposure 
to radiation, the chest X-ray should only be performed after confirming that the subject meets 
all inclusion/exclus ion criteria. At some sites selected by Novartis, the X-ray assessment may 
be replaced b y MRI assessment.
Subjects evaluated at screening for eligibility  should not be screen failed on the basis of a 
medication requiring washout, unless the subject will be unable to complete the washout in the 
appropriate time frame before randomization.
Subjects who prematurely withdraw from the study will not be replaced.

Novartis Confidential Page 46
Amended Protocol Version 02 Track Changes Protocol No. CAIN457F2366
Table 6-1 Assessment schedule
ScreeningStudy Duration (Weeks)
Treatment Period
Activity
SV112
(-8 to -4)
SV212
(-4 to BSL)
BSL
1
2
3
4
6*
8
10*
12
14*
16
18*
20
22*
24
26*
28
30*
32
34*
36
38*
40
42*
44
46*
48
50*
5213
6013
6813
Recruitment
Informed ConsentX
Inclusion/ 
Exclusion CriteriaX X X
Relevant medical 
history/ current 
medical conditionX X
Drug washout 
evaluationX
Smoking history X
CV medical history X
Dem ography X
Psoriasis/ PsA 
medical history and 
previous therapiesX
CASPAR criteria X

Novartis Confidential Page 47
Amended Protocol Version 02 Track Changes Protocol No. CAIN457F2366
ScreeningStudy Duration (Weeks)
Treatment Period
Activity
SV112
(-8 to -4)
SV212
(-4 to BSL)
BSL
1
2
3
4
6*
8
10*
12
14*
16
18*
20
22*
24
26*
28
30*
32
34*
36
38*
40
42*
44
46*
48
50*
5213
6013
6813
Physical exam S S S S S S S S S S S S S S S
Weight X X X
Height X
Vital signs X X X X X X X X X X X X X X X
ECG X
Randomization via 
IRTX
Administration of 
s.c. study treatment 
at study site1, 2, 3, 4X X X X X X X X X X X X X X X X X X X X X X X X X X X X
Prior/Concomitant 
medication/non -
drug therapyX X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X
Hem atology, blood 
chemistry, 
urinalysis5, 10X X X X X
Lipids10X X X X X
PPD6 skin test or 
QuantiFERON TB 
Gold testX

Novartis Confidential Page 48
Amended Protocol Version 02 Track Changes Protocol No. CAIN457F2366
ScreeningStudy Duration (Weeks)
Treatment Period
Activity
SV112
(-8 to -4)
SV212
(-4 to BSL)
BSL
1
2
3
4
6*
8
10*
12
14*
16
18*
20
22*
24
26*
28
30*
32
34*
36
38*
40
42*
44
46*
48
50*
5213
6013
6813
Chest X -ray/MRI7S
Adverse 
Events/SAEs (incl. 
injection site 
reaction, 
occurrence of 
infections)8X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X
Serum pregnancy 
testX
Urine pregnancy 
test9 X X X X X X
ANA X X X
Anti-dsDNA X X X
Anti-CCP X
Rheumatoid factor X

Novartis Confidential Page 49
Amended Protocol Version 02 Track Changes Protocol No. CAIN457F2366
ScreeningStudy Duration (Weeks)
Treatment Period
Activity
SV112
(-8 to -4)
SV212
(-4 to BSL)
BSL
1
2
3
4
6*
8
10*
12
14*
16
18*
20
22*
24
26*
28
30*
32
34*
36
38*
40
42*
44
46*
48
50*
5213
6013
6813
High sensitivity C -
Reactive proteinX X X X X X X X X X X X X X X X
Erythrocyte 
Sedimentation Rate 
(ESR)9X X X X X X X X X X X X X X X
Tender and sw ollen 
joint counts 
(TJC78, SJC76)X X X X X X X X X X X X X X X X
Patient’s 
assessment of PsA 
pain (VAS)X X X X X X X X X X X X X X X
Patient’s global 
assessment of 
disease activity 
(VAS)X X X X X X X X X X X X X X X
Physician’s global 
assessment of X X X X X X X X X X X X X X X

Novartis Confidential Page 50
Amended Protocol Version 02 Track Changes Protocol No. CAIN457F2366
ScreeningStudy Duration (Weeks)
Treatment Period
Activity
SV112
(-8 to -4)
SV212
(-4 to BSL)
BSL
1
2
3
4
6*
8
10*
12
14*
16
18*
20
22*
24
26*
28
30*
32
34*
36
38*
40
42*
44
46*
48
50*
5213
6013
6813
disease activity 
(VAS)
Health Assessment 
Questionnaire 
(HAQ -DI)X X X X X X X X X X X X X X X
BSA assessment X X X X X X X X X X
PASI X X X X X X X X X X

Novartis Confidential Page 51
Amended Protocol Version 02 Track Changes Protocol No. CAIN457F2366
ScreeningStudy Duration (Weeks)
Treatment Period
Activity
SV112
(-8 to -4)
SV212
(-4 to BSL)
BSL
1
2
3
4
6*
8
10*
12
14*
16
18*
20
22*
24
26*
28
30*
32
34*
36
38*
40
42*
44
46*
48
50*
5213
6013
6813
1The individual administering the investigational treatment must not be the investigator or study staff involved in safety and efficacy assessments
2The individual contacting IRT for randomization and treatment assignment must not be the investigator or study staff involved in safety and efficacy assessments
3For visits scheduled through Wee k 4, the study treatment should not be administered less than 7 days from the previous administration
4For visits scheduled after Week 4, the study treatment should not be administered less than 14 days from the previous adminis tration
5Hepatitis B and/or hepatitis C and/or HIV serology testing, performed at local site during screening period, only if required per local medical practice or local 
regulators prior to initiation of therapy. These assessments will be documented in source records only and will n ot be entered into the eCRF
6The PPD skin test can be performed at any time during the screening period but it has to be read w ithin 72 hrs and before ran domization
7If subjects do not have a chest X- ray available within 3 months of screening, an X -ray should be performed after it is certain the subject meets inclusion/exclusion 
criteria in order to minimize unnecessary exposure to X-ray radiation. At some sites selected by Novartis, the X-ray assessment may be replaced by chest MRI 
assessment
8AEs /SAEs oc curring after the subject has provided informed consent must be reported
9Kits will be provided by central lab and test is to be performed locally
10Sample must be obtained fasting.
12Screening visits 1 and 2 w ill be combined for patients complying with previous / concomitant treatments wash -out requirements
13 Subjects w ho discontinue the study should be scheduled for an End-of-Study study visit, 4 w eeks afte r their last study treatment administration, at which time all 
of the assessments listed for the Week 52 visit will be performed. Subjects will return to the study site for the follow -up visits at 12 w eeks and 18 weeks after last 
study treatment (assessmen ts as listed for Week 60 and Week 68).S = assessment to be recorded on source documentation

Novartis Confidential Page 52
Amended Protocol Version 02 Track Changes Protocol No. CAIN457F2366
ScreeningStudy Duration (Weeks)
Treatment Period
Activity
SV112
(-8 to -4)
SV212
(-4 to BSL)
BSL
1
2
3
4
6*
8
10*
12
14*
16
18*
20
22*
24
26*
28
30*
32
34*
36
38*
40
42*
44
46*
48
50*
5213
6013
6813
*The administration of s.c. study treatment may be done at site or at the subject’s home by an independent drug administrator . Concom itant medication/non -drug 
thera py and Adverse Events/SAEs will be collected by telephone, if the administration of study treatment is done at home.

Novartis Confidential Page 53
Amended Protocol Version 02 Track Changes Protocol No. CAIN457F2366
6.1 Information to be collected on screening failures 
Subject may  discontinue from the study  prior to randomization. These subjects are considered 
screening failures.
If a subject discontinues before entering the double -blind treatment period at baseline, IRTmust 
be notified within 2 days and the reason for not being randomized will be entered on the 
Screening Phase Disposition eCRF. In addition, only the following eCRFs should be completed: 
Demograph y eCRF, Informed Consent eCRF , Inclusion/Exclusion eCRF, and the AE eCRF 
should be completed for any Serious Adverse Events (SAEs) that occurred during the screening 
period. AEs that are not serious will be followed by the investigator and collected only in the 
source data.
All subjects who have signed informed consent and are randomized into the Treatment Period 
of the study  will have all AEs occurring after informed consent is signed recorded on the 
Adverse Event eCRF.
Investigators will have the discretion to record abnormal test findings on the medical history
CRF whenever in their judgment, the test abnormality  occurred prior to the informed consent 
signature.
6.2 Patient demographics/other baseline characteristics
Subject demographic and baseline characteristic data to be collected on all subjects and 
recorded in the eCRF include:
Date of birth, age, sex, race, ethnicit y and source of subject referral.
Relevant PsA/Psoriasis and general medical history /current medical condition data until the 
start of investigational treatment, such as date of diagnosis of PsA/Pso riasis, previous 
PsA/Psoriasis therapies, cardiovascular medical history , smoking history  and surgical 
sterilization for females if applicable.
Whenever possible, diagnoses and not sy mptoms will be recorded.
Investigators will have the discretion to record abnormal test findings on the medical history 
CRF whenever in their judgment, the test abnormality  occurred prior to the informed consent 
signature.
6.3 Treatment exposure and compliance
All dates and times of study  treatment administration will be recorded on the appropriate 
Dosage Administration Record eCRF.
Drugs administered prior to start of treatment and other drugs/procedures continuing or started 
during the study  treatment period will be entered in the Prior/Concomitant medications or 
Significant non
-drug therapies eCRF.
Compliance is expected to be 100%, unless temporary interruption is needed for safet y reasons 
as described in (Section 5.5.5 ). Compliance will also be assessed by a Novartis monitor using 
information provided b y the authorized site personnel. 

Novartis Confidential Page 54
Amended Protocol Version 02 Track Changes Protocol No. CAIN457F2366
6.4 Efficacy
The efficacy  outcome measures used in this study  are standard measures used across all PsA 
trials.
American College of Rheumatology  (ACR) 20, 50  responses
Swollen Joint Count (SJC) /Tender Joint Count (TJC)
Patient’s global assessment of disease activity  (VAS)
Physician’s global assessment of disease activity  (VAS)
Patient’s assessment of PsA pain intensity  (VAS)
Health Assessment Questionnaire –Disability  Index (HAQ -DI©)
high sensi tivity  C-Reactive Protein (hsCRP) and Ery throcy te Sedimentation Rate 
(ESR)
Psoriasis Area and Severity  Index (PASI)
All efficacy  assessments should be performed prior to administration of study treatment. Details 
relating to the administration of all PROs are provided in Appendix 2 .
6.4.1 American College of Rheumatology  (ACR) response
The ACR response (Appendix 3) will be used to determine efficacy ( Felson 1995 ). A subject is 
defined as an ACR20 responder if, and onl y if, the following three conditions hold:
they have a ≥ 20% improvement in the number of tender joints (based on 78 joints)
they have a ≥ 20% improvement in the number of swollen joints (based on 76 joints)
they have a ≥ 20% improvement in three of the following five domains:
Patient’s global assessment of disease activity  (measured on a VAS scale, 0 -100) 
Physician’s global assessment of disease activity  (measured on a VAS scale, 0
-100) 
Patient’s assessment of PsA pain (measured on a VAS scale, 0 -100)
Health Assessment Questionnaire –Disability  Index (HAQ -DI©) score
Acute phase reactant (hsCRP or ESR)
ACR50 = 50% improvement in at least 3 of the 5 measures and 50% improvement in the swollen 
and tender joint count.
 

Novartis Confidential Page 55
Amended Protocol Version 02 Track Changes Protocol No. CAIN457F2366
The ACR response is to be assessed at the visits/time points shown in Table 6-1.
6.4.1.1 Tender 78 joint count and swollen 76 joint count
Joint counts will be performed by the independent assessor(s) who must be well trained and 
part of the site personnel. Whenever possible, the same evaluator should perform these 
assessments at all visits.
The 78 joints assessed for tenderness include the 2 temporomandibular, 2 sternoclavicular, 2 
acromioclavicular joints, 2 shoulders, 2 elbows, 2 wrists, 2 first carpometacarpal, 10 
metacarpophalangeal, 10 proximal interphalangeal, 8 distal interphalangeal joints of the hand s, 
2 hips, 2 knees, 2 talo-tibial, 2 mid-tarsal, 10 metatarsophalangeal, 10 proximal interphalangeal, 
and 8 distal interphalangeal joints of the feet. All of these except for the hips are assessed for 
swelling. Joint tenderness and swelling are to be grade d present (1) or absent (0). Synovial fluid 
and/or soft tissue swelling but not bony  overgrowth represents a positive result for swollen joint 
count. Dact ylitis of a digit in the foot or hand counts as one tender and swollen joint.
Data is recorded for tender and swollen joints (right or left side); i.e., a box (yes, no or not 
applicable), needs to be ticked for all joints.
In case a joint is injected with corticosteroids (see restrictions in Section 5.5.7 ), this joint will 
be assessed as both swollen and tender in the SJC and TJC, from injection time onwards.
6.4.1.2 Patient’s assessment of PsA  pain
The patient’s assessment of pain will be performed using a 100 mm visual analog scale (VAS) 
ranging from ‘no pain’ to ‘unbearable pain’ after the question ‘Please indicate with a vertical 
mark ( )through the horizontal line the most pain you had from your psoriatic arthritis today’ .
6.4.1.3 Patient’s global assessment of disease activity
The patient’s global assessment of disease activity  will be performed using a 100 mm (VAS) 
ranging from ‘very  good’ to ‘very  poor’ after the question ‘ Considering all the ways Psoriatic 
Arthritis affects you, please indicate with a vertical mark ( ) through the horizontal line how 
well you are today’ .
6.4.1.4 Physician’s global assessment of disease activity
The physician’s global assessment of disease activity  will be performed using a 100 mm VAS 
ranging from no disease activity  to maximal disease activit y, after the question ‘Considering 
all the ways the disease affects your patient, draw a line on the scale for how well his or her 
condition is today’ . To enhance objectivity , the physician must not be aware of the specific 
subject’s global assessment of disease activity , when performing his own assessment on that 
subject.
6.4.1.5 Health A ssessment Questionnaire – Disability  Index (HA Q- DI)©
The HAQ -DI©was developed by Stanford University  and is one of the most widel y used 
measures to assess the long -term influence of chronic disease on a subject's level o f functional 
ability  and activity  restriction. The disability  assessment component of the HAQ, the HAQ- DI©, 
assesses a subject's level of functional ability  and includes questions of fine movements of the 

Novartis Confidential Page 56
Amended Protocol Version 02 Track Changes Protocol No. CAIN457F2366
upper extremity , locomotor activities of the lower extremity  and activities that involve both 
upper and lower extremities. There are 20 questions in eight categories of functioning including 
dressing, rising, eating, walking, hygiene, reach, grip, and usual activities. The stem of each 
item asks over the past week "Are you able to …" perform a particular task. Each item is scored 
on a 4 -point scale from 0 to 3, representing normal, no difficult y (0), some difficulty (1), much 
difficulty  (2), and unable to do (3).
The purpose of the HAQ -DI©in this study  is to assess the functional ability  of subjects with 
PsA.
6.4.1.6 High Sensitivity C -reactive protein (hsCRP)
Blood for this assessment will be obtained in order to identify the presence of inflammation, to 
determine its severit y, and to monitor res ponse to treatment.
Since the results of this test may unblind study  personnel, results from the central lab will be 
provided for Screening and Baseline only. The hsCRP results from samples collected durin g 
the treatment period will be revealed following d atabase lock onl y.
6.4.1.7 Erythrocyte sedimentation rate (ESR)
Blood for ESR, which is helpful in diagnosing inflammatory  diseases and is used to monitor 
disease activity  and response to therapy , will be obtained at scheduled visits as indicated in 
Table 6
-1.

Novartis Confidential Page 57
Amended Protocol Version 02 Track Changes Protocol No. CAIN457F2366

Novartis Confidential Page 58
Amended Protocol Version 02 Track Changes Protocol No. CAIN457F2366
Presence of enthesitis
If enthesitis is present with any of the 6 sites, the subject is counted as a subject with enthesitis.
6.4.8 Psoriasis A rea and Severity Index (PA SI)
The PASI  (Fredriksson 1978 ; Weisman 2003; Gottlieb 2005) assesses the extent of psoriasis on 
four body  surface areas (head, trunk and upper and lower limbs) and the degree of plaque 
erythema, scaling and thickness. A PASI score will be derived as indicated in Table 6
-3. 

Novartis Confidential Page 59
Amended Protocol Version 02 Track Changes Protocol No. CAIN457F2366
The head, trunk, upper limbs and lower limbs are assessed separatel y for ery thema, thickening 
(plaque elevation, induration) and scaling (desquamation). The average degree of severit y of 
each sign in each of the four body  regions is assigned a score of 0-4. The area covered by lesions 
on each bod y region is estimated as a percentage of the total area of that particular body region. 
Further practical details help the assessment:
The neck is assessed as part of the head.
The axillae and groin are assessed as part of the trunk. 
The buttocks are assessed as part of the lower limbs.
When scoring the severity  of ery thema, scales should not be removed.
Table 6-3 The PA SI scoring sy stem 
Body 
regionErythema (E) Thickening
(plaque elevation,
induration, I)Scaling 
(desquamation, D)Area score
(based on true area% , A)*
Head (H)†0=none 
1=slight 
2=moderate 
3=severe
4=very severe0=none 
1=slight 
2=moderate 
3=severe
4=very severe0=none 
1=slight 
2=moderate 
3=severe
4=very severe0 = no involvement
1 = >0 -< 10%
2 = 10- <30%
3 = 30- <50%
4 = 50- <70%
5 = 70- <90%
6 = 90-100%
Trunk (T)‡0=none 
1=slight 
2=moderate 
3=severe
4=very severe0=none 
1=slight 
2=moderate 
3=severe
4=very severe0=none 
1=slight 
2=moderate 
3=severe
4=very severe0 = no involvement
1 = >0 -< 10%
2 = 10- <30%
3 = 30- <50%
4 = 50- <70%
5 = 70- <90%
6 = 90-100%
Upper 
limbs (U)0=none 
1=slight 
2=moderate 
3=severe
4=very severe0=none 
1=slight 
2=moderate 
3=severe
4=very severe0=none 
1=slight 
2=moderate 
3=severe
4=very severe0 = no involvement
1 = >0 -< 10%
2 = 10- <30%
3 = 30- <50%
4 = 50- <70%
5 = 70- <90%
6 = 90-100%

Novartis Confidential Page 60
Amended Protocol Version 02 Track Changes Protocol No. CAIN457F2366
Body 
regionErythema (E) Thickening
(plaque elevation,
induration, I)Scaling 
(desquamation, D)Area score
(based on true area% , A)*
Lower 
limbs (L)§0=none 
1=slight 
2=moderate 
3=severe
4=very severe0=none 
1=slight 
2=moderate 
3=severe
4=very severe0=none 
1=slight 
2=moderate 
3=severe
4=very severe0 = no involvement
1 = >0 -< 10%
2 = 10- <30%
3 = 30- <50%
4 = 50- <70%
5 = 70- <90%
6 = 90-100%
* Percentage (not score) of body region (not whole body) affected will be entered in the eCRF
†Neck is assessed as part of the Head (H) body region.
‡Axillae and groin are assessed as part of the Trunk (T) body region.
§Buttocks are assessed as part of the Low er limbs (L) body region.
The head and neck, uppe r limbs, trunk and lower limbs correspond to approximately  10%, 20%, 
30% and 40% of the body  surface area, respectively ; the PASI score is calculated using the 
following formula:
PASI  = 0.1(E H+IH+D H)AH+ 0.2(E U+IU+D U)AU+ 0.3(E T+IT+D T)AT+ 0.4(E L+IL+D L)AL
where E = erythema; I = induration; D = desquamation; A = area; H = Head; U = Upper limbs; 
T = Trunk; and L = Lower limbs
PASI  scores can range from a lower value of 0, corresponding to no signs of psoriasis, up to a 
theoretic maximum of 72.0. The investigator is responsible for collecting the components or 
scoring signs and total regional area. More information is provided in Appendix 5 .
6.4.10 Appropriateness of efficacy  assessments 
The efficacy  outcome measures used in this study  are the standard measures used across many 
PsA trials.

Novartis Confidential Page 61
Amended Protocol Version 02 Track Changes Protocol No. CAIN457F2366
6.5 Safet y 
Evaluation of all AEs and SAEs including injection site reactions, abnormal findings in ECG, 
physical examination, vital signs and laboratory  assessments will occur.  
All blood draws and safety assessments should be done prior to study treatment administration. 
Appropriate safet y assessments (e.g. evaluation of AEs and SAEs including injection site 
reactions) should be repeated after the dose is administered.
Evaluation of AE/ SAEs
Physical examination
Vital signs
Height and weight
QuantiFERON TB- Gold test or PPD skin test
Electrocardiogram
Local tolerability  (injection site reactions)
Laboratory evaluations (Hematology , Clinical Chemistry , Lipid Panel, Urinaly sis)
Pregnancy  and assessment of fertility
Tolerability  of secukinumab and adalimumab
6.5.1 Physical examination
The physical examination will include the examination of general appearance, skin, neck, eyes, 
ears, nose, throat, lungs, heart, abdomen, back, lymph nodes, extremities, vascular and 
neurological s ystem.
Information for all phy sical examinations must be included in the source documentation at the 
study  site. Significant findings that are present before signing the ICF must be included in the 
relevant medical history eCRF. Significant findings made after signing the I CF which meet the 
definition of an AE must be recorded in the Adverse Event eCRF.
6.5.2 Vital signs 
Vital signs will include blood pressure and pulse rate measurements after 5 minutes rest in 
sitting position. If possible, vital signs assessments should be performed b y the same stud y site 
staff member using the same validated device throughou t the study .
6.5.3 Height and weight 
Height in centimeters (cm) and body  weight, to the nearest 0.1 kilogram (kg), in indoor clothing 
but without shoes, will be measured.
If possible, bod y weight assessments should be performed b y the same study  site staff member 
using the same scale throughout the stud y.

Novartis Confidential Page 62
Amended Protocol Version 02 Track Changes Protocol No. CAIN457F2366
6.5.4 QuantiFERON TB -Gold test or PPD skin test
Either a QuantiFERON TB-Gold test or a PPD skin test must be performed at screening. 
Subjects with a positive test may  participate in the study  if further work up ( according to local 
practice/guidelines), establishes conclusively  that the subject has no evidence of active 
tuberculosis, OR, if presence of latent tuberculosis is established, then treatment according to 
local country  guidelines must have been initiated prior to enrollment.
6.5.4.1 QuantiFERON TB -Gold test
A QuantiFERON TB-Gold test is to be performed at the second screening visit and the results 
have to be known prior to randomization to determine the subject’s eligibility  for the trial. The 
test will be used to screen the subject population for latent tuberculosis infection.
The test will be performed by the central laboratory . Details on the collection, processing and 
shipment of samples and reporting of results by the central laboratory  are provided in the 
laboratory  manual.
6.5.4.2 PPD skin test
A PPD skin test is to be performed at screening and read before randomization to determine the 
subject’s eligibility  for the trial, if a QuantiFERON test is not performed. The test dose is 
bioequivalent to 5 tuberculin units of standard PPD injected intradermall y, usually  into the volar 
surface of the 
forearm. The site is cleaned and the PPD extract is then injected into the most 
superficial layer under the skin. If given correctl y, the injection should raise a small wheal of 
about 5 mm, which resolves within 10- 15 minutes. 
Because the reaction (induration), will take 48- 72 hours to develop, the subjects must return to 
the study  site within that time for evaluation of the injection site. This will determine whether 
the subject has had a significant reaction to the PPD test. A reaction is measured in millimeters 
of induration (hard swelling) at the site. A PPD skin induration ≥5 mm (or according to local 
practice/guidelines) is interpreted as a positive result.
6.5.5 Laboratory  evaluat ions
A central laboratory  will be used for anal ysis of all specimens listed below (except urinal ysis). 
Details on the collection, shipment of samples and reporting of results b y the central laborator y 
are provided in the laboratory  manual. For the identifi cation of clinically  notable values, see 
Appendix 6 and Appendix 7 . All subjects with laboratory tests containing clinically significant 
abnormal values are to be followed until the values return to normal ranges or until a valid 
reason, other than treatment related AE, is defined.
6.5.5.1 Hematology
Hemoglobin, platelets, red blood cell (RBC), white blood cell (WBC) and differential white 
blood cell counts w ill be measured at scheduled visits.

Novartis Confidential Page 63
Amended Protocol Version 02 Track Changes Protocol No. CAIN457F2366
6.5.5.2 Clinical chemistry
Serum chemistries will include glucose, urea, creatinine, total bilirubin, AST (SGOT), ALT 
(SGPT), GGT, alkaline phosphatase, sodium, potassium, bicarbonate, calcium, phosphorus, 
total protein, albumi n, and uric acid.
6.5.5.3 Urinaly sis
Dipsticks will be provided by the central laboratory  to the sites for local urinaly sis assessments. 
The urinaly sis results for standard parameters such as protein, glucose, blood, and WBCs will 
be recorded in the appropriate eC RF.
6.5.5.4 Lipid panel
A lipid profile including High Density  Lipoprotein (HDL), Low Density  Lipoprotein (LDL), 
total cholesterol, and trigly cerides will be measured from a fasting blood sample.
6.5.6 Electrocardiogram (ECG) 
A standard 12-lead ECG will be performed asindicated in Table 6-1at the Baseline visit. ECGs 
must be recorded after 10 minutes rest in the supine position to ensure a stable baseline. The 
preferred sequence of cardiovascular data collection during study  visits 
is ECG collection 
followed by vital signs and blood sampling. The Fridericia QT correction formula (QTcF) 
should be used for clinical decisions.
Each ECG tracing should be labeled with study  number, subject initials, subject number, date 
and time, andfiled in the study  site source documents. For any ECGs with subject safet y 
concerns, two additional ECGs should be performed to confirm the safety  finding. Clinicall y 
significant ECG findings at baseline must be discussed with the sponsor before administr ation 
of investigational treatment. 
Clinically  significant abnormalities must be recorded on the relevant section of the medical 
history /Current medical conditions/AE eCRF as appropriate.
6.5.7 Pregnancy  and assessments of fertility  
The study  treatment must not be given to pregnant women; therefore, effective methods of birth 
control must be used for women of childbearing potential (see exclusion criteria definitions, 
Section 4.2).
A serum β
-hCG test will be performed in all women at screening. All women who are not 
surgically  sterile or post-menopausal (as defined in Section 4.2) at screening, will have local 
urine pregnancy  tests as indica ted in Table 6
-1. A positive urine pregnancy  test requires 
immediate 
interruption of study  treatment until serum β -hCG is performed and found to be 
negative. If positive, the subject must discontinue stud y treatment.
6.5.8 Tolerability  of Investigational Treatments
Tolerability  will be assessed by AEs, laboratory  values, injection site reaction,  
.

Novartis Confidential Page 64
Amended Protocol Version 02 Track Changes Protocol No. CAIN457F2366
6.5.9 Additional parameters
Blood will be obtained at the first screening visit (Visit 1) for anti-CCP antibodies and the 
Rheumatoid Factor (RF) assessment. Antinuclear antibody  (ANA) and anti-double stranded 
deox yribonucleic acid antibody  (anti-dsDNA) antibodies will also be assesse d at visits/time 
points indicated in Table 6-1.
6.5.11 Appropriateness of safety  measurements 
The safet y measures used in this study  are standard for a use of a biologic in patients with PsA. 
A chest X -ray or MRI at screening (or within 3 months prior to screening) is performed to rule 
out the presence of a pulmonary  malignancy  of infectious process (in particular, tuberculosis).

Novartis Confidential Page 65
Amended Protocol Version 02 Track Changes Protocol No. CAIN457F2366
The total amount of radiation exposure that results from the screening X-ray measurement is 
considered to involve minimal risk and is necessary to ensure reliable safet y measures before 
the treatment with a biologic.
The safet y assessments selected are standard and adequate for this indication/subject population.
6.6 Other assessments
The other assessments planned for the study  are:
Quality  of Life questionnaires/ Patient re ported outcomes (PROs)
6.6.1 Health -related Quality of Life 
The impact of PsA on various aspects of subjects’ health-related quality  of life (HRQoL) will 
be assessed using the following validated instruments:
HAQ- DI©(see Section 6.4.1.5)
All questionnaires will be available, where possible, in the local languages of the participating 
countries and should be completed by subjects before they see the study  physician. All 
questionnaires will be completed at the defined visits / time points li
sted in the Table 6-1and 
prior to the subject seeing the investigator for any clinical assessment or evaluation. The 
questionnaires will be in the respondent’s local language. The subject should be given sufficient 
instruction, space, time and privacy  to complete the questionnaires. The study  coordinator 
should check the questionnaires for completeness and encourage the subject to complete any 
missing responses. Completed questionnaires should be reviewed and assessed by the 
investigator, before the clinical examination, for responses which may indicate potential AEs 
or SAEs. This assessment should be documented in the source records. If AEs or SAEs are 
confirmed, the investigator should record the events as per instructions given in the relevant 
section of the protocol (see Section 7.1 and Section 7.2 ).
Guidelines for administering the PRO questionnai res can be found in Appendix 2 .

Novartis Confidential Page 66
Amended Protocol Version 02 Track Changes Protocol No. CAIN457F2366

Novartis Confidential Page 67
Amended Protocol Version 02 Track Changes Protocol No. CAIN457F2366

Novartis Confidential Page 68
Amended Protocol Version 02 Track Changes Protocol No. CAIN457F2366

Novartis Confidential Page 69
Amended Protocol Version 02 Track Changes Protocol No. CAIN457F2366

Novartis Confidential Page 70
Amended Protocol Version 02 Track Changes Protocol No. CAIN457F2366
7 Safety  monitoring 
7.1 Adverse events 
An adverse event (AE) is any untoward medical occurrence (e.g., any unfavorable and 
unintended sign, including abnormal laboratory  findings, symptom or disease) in a clinical 
investigation subject after providi ng informed consent for participation in the study  until the 
end of study  visit. Therefore, an AE may  or may  not be temporally  or causally  associated with 
the use of a medicinal (investigational) product. 
In addition, all reports of intentional misuse andabuse of the product are also considered an 
adverse event irrespective if a clinical event has occurred.
The occurrence of AEs must be sought b y non -directive questioning of the subject at each visit 
during the study . Adverse events also may be detected when they are volunteered by the subject 
during or between visits or through ph ysical examination, laboratory test, or other assessments.

Novartis Confidential Page 71
Amended Protocol Version 02 Track Changes Protocol No. CAIN457F2366
Abnormal laboratory  values or test results constitute AEs only  if they  fulfill at least one of the 
following criteria:
they induce clinical signs or sy mptoms, 
they are considered clinically significant, 
they require therapy . 
Clinically  significant abnormal laboratory  values or test results must be identified through a 
review of values outside of normal ranges/clinically notable ranges, significant changes from 
baseline or the previous visit, or values which are considered to be non- typical in a patient with 
underly ing disease. Investigators have the responsibility  for managing the safet y of individual 
subject and identif ying AEs. Alert ranges for laboratory  and other test abnormalities are 
included in Appendix 7 .
Adverse events must be recorded in the Adverse Events CRF under the signs, symptoms or 
diagnosis associated with them, accompanied by  the following information:
the severit y grade
mild: usually  transient in nature and generally  not interfering with normal activities
moderate: sufficiently  discomforting to interfere with normal activities
severe: prevents normal activities 
Its relationship to the study  treatment and other investigational treatment 
“No Relationship to study  treatment or other investigational treatment ”or
“Relationship to study  treatment ”or
“Relationship to other investiga tional treatment ”or 
“Relationship to both study  treatment and other investigational treatment or 
indistinguishable”
its duration (start and end dates) or if the event is ongoing an outcome of not 
recovered/not resolved must be reported
whether it constit utes a serious adverse event (SAE -See Section 7.2 for definition of 
SAE) and which seriousness criteria have been met
action taken regarding investigational treatment. 
The action taken to treat the AE
should be recorded on the Adverse Event eCRF.
All adverse events must be treated appropriately . Treatment may include one or more of the 
following: 
no action taken (e.g. further observation only ) 
investigational treatment dosage increased/reduced
invest igational treatment interrupted/withdrawn
concomitant medication or non- drug therap y given 
patient hospitalized/patient’s hospitalization prolonged (see Section 7.2 for definition 
of SAE)
its outcome (not recovered/not resolved; recovered/resolved; recovering/resolving, 
recovered/resolved with sequelae; fatal; or unknown)

Novartis Confidential Page 72
Amended Protocol Version 02 Track Changes Protocol No. CAIN457F2366
Once an AE is detected, it must be followed until its resolution or until it is judged to be 
permanent, and assessment must be made at each visit (or more frequentl y, if necessar y) of any 
changes in severit y, the suspected relationship to the study  drug, the interventions required to 
treat it, and the outcome. 
The investigator must also instruct each subject to report any new AE (beyondthe protocol 
observation period) that the subject, or the subject’s personal physician, believes might 
reasonabl y be related to study  treatment. This information must be recorded in the investigator’s 
source documents; however, if the AE meets the criteri a of an SAE, it must be reported to 
Novartis.
7.2 Serious adverse events 
7.2.1 Definition of SA E 
An SAE is defined as any AE [appearance of (or worsening of any pre-existing)] undesirable 
sign(s), s ymptom(s) or medical conditions(s)) which meets an y one of the following criteria:
is fatal or life -threatening 
results in persistent or significant disability /incapacity
constitutes a congenital anomaly /birth defect
requires inpatient hospitalization or prolongation of existing hospitalization, unless 
hospitalizatio n is for:
routine treatment or monitoring of the studied indication, not associated with any  
deterioration in condition (specify  what this includes)
elective or pre -planned treatment for a pre -existing condition that is unrelated to the 
indication under st udy and has not worsened since signing the informed consent
treatment on an emergency  outpatient basis for an event not fulfilling any  of the 
definitions of a SAE given above and not resulting in hospital admission 
social reasons and respite care in the a bsence of any  deterioration in the patient’s 
general condition
is medically  significant, e.g. defined as an event that jeopardizes the patient or may  
require medical or surgical intervention.
All malignant neoplasms will be assessed as serious under “medic ally significant” if other 
seriousness criteria are not met. 
Life-threatening in the context of a SAE refers to a reaction in which the patient was at risk of 
death at the time of the reaction; it does not refer to a reaction that hypothetically  might have 
caused death if it were more severe (please refer to Annex I V, ICH -E2D Guideline).
Medical and scientific judgment should be exercised in deciding whether other situations should 
be considered serious reactions, such as important medical events that migh t not be immediately 
life threatening or result in death or hospitalization but might jeopardize the subject or might 
require intervention to prevent one of the other outcomes listed above. Examples of such events 
are intensive treatment in an emergency  room or at home for allergic bronchospasm, blood 
dyscrasias or convulsions that do not result in hospitalization or development of dependency or 
abuse (please refer to Annex I V, ICH -
E2D Guideline).

Novartis Confidential Page 73
Amended Protocol Version 02 Track Changes Protocol No. CAIN457F2366
Any suspected transmission via a medicinal product of an inf ectious agent is also considered a 
serious adverse reaction.
All AEs (serious and non-serious) are captured on the CRF; SAEs also require individual 
reporting to Drug Safety  and Epidemiology  as per Section 7.2.2.
7.2.2 SAE reporting 
To ensure patient safet y, every SAE, regardless of causalit y, occurring after the patient has 
provided informed consent and until 10 weeks (70days) after the last study  visit, or 12 Weeks 
(84 days) following the last administration of study treatment, or 30 days after the subject has 
stopped study  participation (whichever is later) must be reported to Novartis within 24 hours of 
learning of its occurrence. 
Any SAEs experienced after this period should only  be reported to Novartis if the investigator 
suspects a causal relationship to study  treatment. 
All follow -up information for the SAE including information on complications, progression of 
the initial SAE and recurrent episodes must be reported as follow -up to the original episode 
within 24 hours of the investigator receiving the follow -up information. An SAE occurring at a 
different time interval or otherwise considered completely  unrelated to a previously  reported 
one must be reported separatel y as a new event.
Information about all SAEs is collected and recorded on the Serious Adverse Event Report 
Form; all applicab le sections of the form must be completed in order to provide a clinically 
thorough report. The investigator must assess the relationship of each SAE to each specific 
component of study treatment, (if study treatment consists of several components) complet e the 
SAE Report Form in English, and submit the completed form within 24 hours to Novartis. 
Detailed instructions regarding the submission process and requirements for signature are to be 
found in the investigator folder provided to each site.  
Follow -upinformation is submitted as instructed in the investigator folder. Each re-occurrence, 
complication or progression of the original event must be reported as a follow -up to that event 
regardless of when it occurs. The follow -up information should describe whether the event has 
resolved or continues, if and how it was treated, whether the blind was broken or not, and 
whether the patient continued or withdrew from study  participation. 
If the SAE is not previously documented in the Investigator’s Brochure or Package Insert (new 
occurrence) and is thought to be related to the study treatment a Drug Safety and Epidemiolog y 
Department associate may urgentl y require further information from the investigator for health 
authority  reporting. Novartis may need to issue an Investigator Notification (IN) to inform all 
investigators involved in any study  with the same study  treatment that this SAE has been 
reported. Suspected Unexpected Serious Adverse Reactions (SUSARs) will be collected and 
reported to the competent authorities and relevant ethics committees in accordance with EU 
Guidance 2011/C 172/01 or as per national regulatory requirements in participating countries.

Novartis Confidential Page 74
Amended Protocol Version 02 Track Changes Protocol No. CAIN457F2366
7.3 Liver safety  monitoring 
To ensure patient safet y and enhance reliability  in determining the hepatotoxic potential of an 
investigational drug, a standardized process for identification, monitoring and evaluation of 
liver events has to be followed. 
The following two categories of abnormalities / adverse events have to be considered during 
the course of the study  (irrespective of whether classified/reported as (S)AE):
Liver laboratory  triggers, which will require repeated assessments of the abnormal 
laboratory  parameter
Liver events , which will require close observation, follow -up monitoring and completion 
of the standard base liver CRF
Please refer to Table 18-1 in Appendix 6for complete definitions of liver laboratory  triggers 
and liver events. 
Every  liver laboratory  trigger or liver event as defined in Table 18 -
1inAppendix 6 should be 
followed up b y the investigator or designated personal at the trial site as s ummarized below. 
Detailed information is outlined in Table 18-2 in Appendix 6 .
For the liver laboratory  trigger:
Repeating the liver function test (LFT) within the next week to confirm elevation or 
resolution.
These LFT repeats should be performed using the central laboratory  if possible. If this is not 
possible, then the repeats can be performed at a local laboratory  to monitor the safet y of the 
subject. Repeats laboratory must then be performed at central laboratory as soon as possible. If 
a liver event is subsequently  reported, any  local LFTs previousl yconducted that are associated 
with this event should be reported on the Liver CRF. If the elevation is confirmed, close 
observation of the patient will be initiated, including consideration of treatment interruption if 
deemed appropriate.
For the liver ev ents:
Repeating the LFT to confirm elevation as appropriate
Discontinuation of the investigational drug if appropriate
Hospitalization of the patient if appropriate
A causalit y assessment of the liver event via exclusion of alternative causes (e.g. disease , 
co-medications)
An investigation of the liver event which needs to be followed until resolution. 
These investigations can include serology  tests, imaging and pathology  assessments, 
hepatologist’s consultancy , based on investigator’s discretion.  All fol low-up information, and 
the procedures performed must be recorded on the appropriate CRF, including the liver event 
overview CRF.

Novartis Confidential Page 75
Amended Protocol Version 02 Track Changes Protocol No. CAIN457F2366
7.4 Renal safety  monitoring 
To date, there has been no safet y signal for nephrotoxicity  with secukinumab in over 12,000 
patients and healthy  subjects exposed, and from a mechanism of action standpoint there is no 
known effect of blocking IL-17A on the kidney . All subjects with laboratory  tests resulting in 
clinically  significant abnormal values (see Appendix 7 for notable laboratory  values) are to be 
followed until the values return to normal ranges or until a valid reason, other than treatment 
related AE, is defined. Standard renal function tests (blood urea nitrogen, serum creatinine) will 
be obtained at regular intervals, but special measures for renal safet y monitoring are not planned.
7.5 Reporting of study  treatment errors including misuse/abuse 
Medication errors are unintentional errors in the prescribing, dispensing, administ ration or 
monitoring of a medicine while under the control of a healthcare professional, patient or 
consumer (EMA definition).
Misuse refers to situations where the medicinal product is intentionally  and inappropriatel y used 
not in accordance with the prot ocol.
Abuse corresponds to the persistent or sporadic, intentional excessive use of a medicinal product, 
which is accompanied b y harmful ph ysical or ps ychological effects.
Study  treatment errors and uses outside of what is foreseen in the protocol will be collected in 
the DAR (dose administration record) eCRF irrespective of whether or not associated with an 
AE/SAE and reported to 
Safety  only if associated with an SAE. Misuse or abuse will be 
collected and reported in the safet y database irrespective of it being associated with an AE/SAE.
Table 7- 1 Study  treatment 
Treatment error 
typeDocument in Dose 
Administration 
(DAR) eCRF (Yes/No)Document in A E 
eCRFComplete SA E form
Unintentional study 
treatment errorYes Only if associated with 
an AEOnly if associated with an 
SAE
Misuse/Abuse Yes Yes, Yes, even if not 
associated with a SAE
7.6 Pregnancy  reporting
To ensure subject safet y, each pregnancy  occurring while the patient is on study  treatment must 
be reported to Novartis/Contract Research Organization (CRO) within 24 hours of learning of 
its occurrence. The pregnancy  should be followed up to determine outcome, including 
spontaneous or voluntary termination, details of the birth, and the presence or absence of any 
birth defects, congenital a bnormalities, or maternal and/or newborn complications.
Pregnancy  must be recorded on the Pharmacovigilance Pregnancy  Form and reported by the 
investigator to the local Novartis Drug Safet y and Epidemiology  Department. Pregnancy 
follow -up should be recorde d on the same form and should include an assessment of the 
possible relationship to the study  treatment. 

Novartis Confidential Page 76
Amended Protocol Version 02 Track Changes Protocol No. CAIN457F2366
Any SAE experienced during the pregnancy  and unrelated to the pregnancy  must be reported 
on a SAE form.
8 Data revie w and database management 
8.1 Site moni toring 
Before study  initiation, at a site initiation visit or at an investigator’s meeting, a Novartis 
representative will review the protocol and data capture requirements (i.e. eCRFs) with the 
investigators and their staff. During the study , Novartis employs several methods of ensurin g 
protocol and Good Clinical Practice (GCP) compliance and the quality /integrity  of the sites’ 
data. The field monitor will visit the site to check the completeness of patient records, the 
accuracy  of data capture / data ent ry, the adherence to the protocol and to GCP, the progress of 
enrollment, and to ensure that study  treatment is being stored, dispensed, and accounted for 
according to specifications. Key study personnel must be available to assist the field monitor 
during these visits.  Continuous remote monitoring of each site’s data may be performed by a 
centralized Novartis CRA organization. Additionally , a central analytics organization may 
analyze data and identify risks & trends for site operational parameters and provide reports to 
Novartis Clinical Teams to assist with trial oversight.
The investigator must maintain source documents for each subject in the study , consisting of 
case and visit notes (hospital or clinic medical records) containing demographic and medic al 
information, laboratory  data, electrocardiograms (ECGs), and the results of any other tests or 
assessments. All information on CRFs must be traceable to these source documents in the 
subject's file. The investigator must also keep the original informed consent form signed by the 
patient (a signed cop y is given to the subject).
The investigator must give the monitor access to all relevant source documents to confirm their 
consistency  with the data capture and/or CRF entries. Novartis monitoring standards require 
full verification for the presence of informed consent, adherence to the inclusion/exclusion 
criteria, documentation of SAEs, and of data that will be used for all primary  variables. 
Additional checks of the consistency  of the source data with the CRFs are performed according 
to the study -specific monitoring plan. No information in source documents about the identity 
of the subjects will be disclosed.
8.2 Data collection 
Designated investigator staff will enter the data required by the protocol into the OC/RDC 
system. Designated investigator site staff will not be given access to the s ystem until they have 
been trained. 
Automatic validation procedures within the system check for data discrepancies during and 
after data entry  and, by generating appropri ate error messages, allow the data to be confirmed 
or corrected online by the designated investigator site staff. The Investigator must certify  that 
the data entered into the electronic Case Report Forms are complete and accurate. After 
database lock, the investigator will receive copies of the patient data for archiving at the 
investigational site. 

Novartis Confidential Page 77
Amended Protocol Version 02 Track Changes Protocol No. CAIN457F2366
8.3 Database management and quality  control 
Data from the CRFs are entered into the study  database by Novartis Data Management staff 
using single data entry  and by referring to the scanned image of the CRF.
Novartis staff review the data entered into the CRFs by investigational staff for completeness 
and accuracy  and instruct the site personnel to make any required corrections or additions. 
Queries are sent to theinvestigational site using an electronic data query . Designated 
investigator site staff is required to respond to the query  and confirm or correct the data. If the 
electronic query  system is not used, a paper Data Query  Form will be faxed to the site. Site 
personnel will complete and sign the faxed copy and fax it back to Novartis staff that will make 
the correction to the database. The signed copy  of the Data Query  Form is kept at the 
investigator site.
Concomitant medications entered into the database will be coded using the World health 
Organization (WHO) Drug Reference List, which employ s the Anatomical Therapeutic 
Chemical classification system. Concomitant procedures, non-drug therapies and AEs will be 
coded using the Medical Dictionary  for Regulatory
Activities (MedDRA) terminology .
Laboratory  samples will be processed centrall y and the results will be sent electronicall y to 
Novartis (or a designated CRO).
Patients/subjects will fill in their PRO data in a site based tablet. The system will be supplie d 
by a vendor(s), who will also manage the database. The database will be sent electronically  to 
Novartis personnel (or designated CRO).
Randomization codes and data about all study  drug(s) dispensed to the patient and all dosage 
changes will be tracked using an IRT system. The system will be supplied by Novartis, who 
will also manage the database. Each occurrence of a code break via IRT will be reported to the 
clinical team and monitor.  The code break functionality  will remain available until study  shut 
down or upon request of Novartis. 
The occurrence of relevant protocol deviations will be determined. After these actions have 
been completed and the database has been declared to be complete and accurate, it will be 
locked and the treatment codes will be unblinded and made available for data analysis. Any 
changes to the database after that time can only be made after written agreement by Novartis 
Development management.
 
 
 
 
8.4 Data Mon itoring Committee 
A Data Monitoring Committee is not planned for this study .

Novartis Confidential Page 78
Amended Protocol Version 02 Track Changes Protocol No. CAIN457F2366
8.5 Adjudication Committee
An independent external adjudication committee may be used to monitor specific safet y events, 
including, but not limited to clinically  significant cardio -and cerebrovascular events. The 
events will be reviewed and adjudicated in a blinded fashion as they occur during the conduct 
of the trial.
Details regarding the definition of AEs of special interest as well as the adjudication process 
will be available in the relevant secukinumab Adjudication Committee charter.
9 Data analy sis 
Summary  statistics for continuous variables include N, mean, standard deviation, minimum, 
lower quartile, median, upper quartile, and maximum. For binary  or discrete variables the 
absolute number of subjects in each category  and relative frequencies will b e provided. 
Unless otherwise specified, p -values will be presented as 2 -sided p-values and the ty pe I error 
rate (alpha) will be 5%.
Inferential efficacy  comparison of secukinumab 300mg with adalimumab will be performed at 
Week 52 unless otherwise specifi ed.
Efficacy  and safet y data for the entire treatment period will be presented b y treatment groups.
9.1 Analysis sets 
The following anal ysis sets will be used in this trial:
Randomized set:The randomized set will be defined as all subjects who were randomize d. 
Unless otherwise specified, mis-randomized subjects (mis- randomized in Interactive Voice 
Response (IVR)) will be excluded from the randomized set.
Mis-randomized subjects are defined as those subjects who were mistakenly  randomized into 
the IVR prior tothe site confirming all eligibility  criteria had been met and to whom no study  
medication was given. Mis -randomized subjects are treated as screen failures.
Full analysis set (FAS) : The FAS will be comprised of all subjects from the randomized set to 
whom study  treatment has been assigned. Following the intent -to-treat principle, subjects will 
be anal yzed according to the treatment assigned to at randomization.
Safety set: The safet y set includes all subjects who took at least one dose of study  treatment 
during the treatment period. Subjects will be evaluated according to treatment received.
9.2 Subject demographics and other baseline characteristics 
Demographics and baseline characteristics
Summary  statistics will be presented for continuous demographic and baseline characteristic 
variables for each treatment group and for all subjects in the randomized set. The number and 
percentage of subjects 
in each category  will be presented for categorical variables for each 
treatment group and all subjects.

Novartis Confidential Page 79
Amended Protocol Version 02 Track Changes Protocol No. CAIN457F2366
The followi ng demographic variables and baseline disease characteristics will be summarized 
by treatment groups:
Gender, age, race, ethnicity , weight, height, and BMI
ACR components and other disease -related measures (e.g. , presence of enthesitis, 
, time since first diagnosis of psoriatic arthritis, , subjects 
with psoriasis ≥ 3%). 
Medical history
Any significant prior or active medical condition at the time of signing informed consent will 
be coded using the MedDRA dictionary . These medical conditions will be summarized by 
primary  system organ class and preferred term.
To establish a baseline level of cardiovascular risk, the number and percentage of subjects with 
pre-solicited cardiovascular risk factors will be summarized by treatm ent group. The number 
of cardiovascular risk factors that each subject has will also be summarized by treatment group. 
If it is unknown whether or not a subject currently  or previously  experienced a specific 
cardiovascular risk factor, it will be assumed that cardiovascular risk factor did not occur for 
that subject.
9.3 Treatments 
Study treatment
The analysis of study  treatment data will be based on the safet y set. The number of active 
injections received will be presented b y treatment group. 
The duration of exposure to study  treatment will also be summarized by treatment group. In 
addition, the number and percentage of subjects with cumulative exposure levels (e.g. any 
exposure, ≥ 1 week, ≥ 2 weeks, ≥ 3 weeks, ≥ 4 weeks, ≥ 8 weeks, etc.) will be presented.
Prior and concomitant medication
Prior and concomitant medications (including Rescue medications defined in Section 5.5.6) will 
be summarized in separate tables by treatment group. Prior medications are defined as 
treatments taken and stopped prior to first dose of study  treatment. Any medication given at 
least once between the day of first dose of randomized study  treatment and the date of the last 
study  visit will be a concomitant 
medication, including those which were started pre-baseline 
and continued to the period where study treatment is administered.
Medications will be presented in alphabetical order, by  Anatomical Therapeutic Classification 
(ATC) codes and grouped by anatomical main group. Tables will sh ow the overall number and 
percentage of subjects receiving at least one treatment of a particular ATC code and at least one 
treatment in a particular anatomical main group.
Significant prior and concomitant non-drug therapies and procedures will be summari zed by 
primary  system organ class and MedDRA preferred term.

Novartis Confidential Page 80
Amended Protocol Version 02 Track Changes Protocol No. CAIN457F2366
The number and percentage of subjects receiving prior and concomitant PsA therap y will be 
presented by randomized treatment group as well as the reasons for stopping their therapies 
(primary  lack of efficacy , secondary  lack of efficacy , lack of tolerability , other).
9.4 Analysis of the primary  variable(s)
Details of the testing strategy  including primary  and secondary  endpoints are provided in 
Secti on 9.5.1.
9.4.1 Variable(s)
The primary  efficacy  endpoint will be ACR20 response at Week 52 for superiorit y test to 
compare 300 mg secukinumab with adalimumab. The analysis of the primary  efficacy endpoint 
will be based on the FAS subjects. Primarily , CRP will be used instead of ESR to calculate 
ACR response; ESR will only  be used in the event CRP is missing.
9.4.2 Statistical model, hypothesis, and method of analy sis
The statistical hypothesis for ACR20 being tested for superiorit y test is that there is no 
difference in the proportion of subjects fulfilling the ACR20 criteria at Week 52 in the 
secukinumab 300 mg group vs. adalimumab.
Let pj denote the proportion of ACR20 responders at Week 52 for treatment regimens j, j=0, 1 
where 
0 corresponds to adalimumab,
1 corresponds to secukinumab 300 mg
In statistical terms, H1: p1 = p0, HA1: p1 ≠p0, i.e.
H1: secukinumab is not different to adalimumab regimen for signs and symptoms (ACR20 
response) at Week 52.
The primary  endpoint of ACR20 at Week 52 in the FAS will be evaluated using a logistic 
regression model with treatment as a factor and weight as a covariate. Odds ratios will be 
computed for comparisons of secukinumab 300 mg vs. adalimumab regimen utilizing the 
logistic regression model fitted.
9.4.3 Handling of missing values/censoring/discontinuations
The primary  and secondary  estimands focus on the difference between the treatment groups in 
the proportion of patients achieving monotherap y ACR20 response (or other response variables) 
at week 52 in FAS patients.  Monothe rapy response is defined as achieving the requirements 
for the clinical response (e.g. ACR20) and not prematurely discontinuing study medication and 
not taking concomitant MTX/cDMARD (composite estimands).  Missing data for ACR20 
response and other binary  efficacy  variables (e.g. ACR50, 
,  PASI 90,  etc.) for data up 
to Week 52 will be handled by multiple imputation. Multiple imputation (MI) is a simulation 
based approach where missing values are replaced by multiple Bayesian draws from the 
conditional distribution of missing data given the observed data and covariates, creating 
multiple completed data sets. These completed data sets can then be analyzed using standard 

Novartis Confidential Page 81
Amended Protocol Version 02 Track Changes Protocol No. CAIN457F2366
methods. Within this analysis the ACR composites or PASI score will be imputed and res ponse 
variables will be derived based on the imputed scores. In the multiple imputation analy sis the 
response status will be imputed based on the individual treatment arm information.
Continuous variables (e.g. ACR components, DAS, etc.) will be analy zed using a mixed -effects 
repeated measures model (MMRM) which is valid under the missing at random (MAR) 
assumption. For analy ses of these parameters, if all post-BSL values are missing then these 
missing values will not be imputed and this subject will be removed 
from the analysis of the 
corresponding variable, i.e. it might be that the number of subjects providing data to an analysis 
is smaller than the number of subjects in the FAS.
9.4.4 Supportive analy ses 
Sensitivity  analyses and supportive analyses will be conducted in order to provide evidence that 
the results seen from the primary  analysis are robust. These analy ses will center on the 
deviations in model assumptions, and the treatment of missing data.
In order to determine the robustness of the logistic regression model used for the primary 
analysis, ACR20 response at Week 52 may also be evaluated using a non-parametric regression 
(Koch 1998) model with the same independent variables as the logistic regress ion model. In 
addition, further logistic regression models may be conducted which explore the impact of other 
BSL or disease characteristics on response.
The impact of missing data on the analy sis results will be assessed as well by repeating the 
logistic regression model using ways to handle missing data. These may include, but are not 
limited to: 
Non-responder Imputation
Observed data analy sis
Additional sensitivity  analyses will be conducted to examine the effect of taking concomi tant 
treatment of MTX and/or other cDMARDs along with study  drug and /or the effect of treatment 
discontinuation without rescue medication but remaining in the study on the primary  endpoint.
9.5 Analysis of secondary  variables
9.5.1 Efficacy  variables
The secondary  efficacy endpoints are listed below. Secondary  efficacy endpoints will be 
analyzed using the FAS population unless otherwise specified.
PASI 90 response at Week 52 in Superiority  test for secukinumab 300 mg 
ACR50 response at Week 52 in Superiority  test for 
secukinumab  300 mg 
Change from baseline in HAQ -DI©score at Week 52 in Superiority  test for secukinumab 
300 mg 
Resolution of enthesitis at Week 52 in Superiority  test for secukinumab 300 mg 

Novartis Confidential Page 82
Amended Protocol Version 02 Track Changes Protocol No. CAIN457F2366
Testing strategy
The following h ypotheses will be included in the hierarchical testing strategy, and t ype-I-errors 
will be set such that family -wise two-sided type -I- error of 5% is kept. The inferential testing 
procedure will only continue if the previous test was rejected at the appropriate type-I- error rate 
as spec ified after Figure 9 -1. 
Primary  objectives (detailed in Section 9.4.2 )
H1: secukinumab 300 mg is not different to adalimumab regimen with respect to ACR20 
response at Week 52.
Secondary  objectives
The same method of imputation for binary  endpoints that is being used for the primary  is also 
being used for secondary endpoints
H2: secukinumab 300 mg is not different to adalimumab regimen with respect to PASI 90 
response at Week 52 
H3: secukinumab 300 mg is not different to adalimumab regimen with respect to ACR50 
response at Week 52 
H4: secukinumab 300 mg is not different to adal
imumab regimen with respect to the 
change from baseline in HAQ -DI©at Week 52 
H5: secukinumab 300 mg is not different to adalimumab regimen with respect to 
resolution of enthesitis at Week 52 
Figure 9-1 Testing Strategy
The famil y-wise error rate will be set to two- sided α=5% and it will be controlled with the 
proposed hierarchical testing strategy . 
If H1 is rejected at α, the hy pothesis H2 will be tested at α. If H2 is rejected at α, H3 
will be tested at α and so on. 
ACR50 PASI90ACR20
HAQ-DI 
change
Resolution 
of enthesitis

Novartis Confidential Page 83
Amended Protocol Version 02 Track Changes Protocol No. CAIN457F2366
ACR50 at Week 52
Response at Week 52 to ACR50 in the FAS will be evaluated using a logistic regression model 
with treatment as a factor and weight as a covariate.
PASI90 response
PASI 90 response at Week 52 will be evaluated using a logistic regression model with treatment 
as a factor and weight as a covariate.
Physical function (HA Q-DI©)
Between -treatment differences in the change in HAQ -DI©will be evaluated using a MMRM 
with treatment regimen, analysis visit as factors, and weight and baseline HAQ- DI©score as 
continuous covariates. Treatment by analysis visit and baseline by analysis visit will be included 
as interaction terms in the model. An unstructured covariance structure will be assumed for this 
model. The significance of the treatment effects f or secukinumab regimens at different anal ysis 
visits will be determined from the pairwise comparisons performed between secukinumab 
regimen and adalimumab at the appropriate anal ysis visits.
Resolution of enthesitis
Resolution (presence to absence) of enthesitis at Week 52 will be evaluated using a logistic 
regression model with treatment as a factor and weight as a covariate.

Novartis Confidential Page 84
Amended Protocol Version 02 Track Changes Protocol No. CAIN457F2366
9.5.3 Safety  variables 
Adverse events
Treatment -emergent AEs (TEAEs, adverse events that started after the first dose of study  
treatment or events present prior to the first dose of study  treatment but increased in severit y 
based on preferred term) will be summarized up to 12 weeks (84 days) after the last dose. Non -
treatment -emergent AEs will be listed in a listing but not summarized.
TEAEs will be summarized by presenting, for each treatment group, the number and percentage 
of subjects having any AE, having an AE in each primary  system organ class and having each 
individual AE (preferred term). Summaries will also be presented for AEs by severit y and for 
study  treatment related AEs. If a subject reported more than one AE with the same preferred 
term, the AE with the greatest severit y will be presented. If a subject reported more than one 
AE within the same primary s ystem organ class, the subject will be counted only once with the 
greatest severity  at the system organ class level, where applicable. SAEs will also be 
summarized. 
As appropriate, the incidence of AEs will be presented per 100 subject -years of exposure. 
Separate summaries will be provided for death, SAE, other TEAEs leading to study  treatment 
interruption or study  treatment discontinuation.
A graphical display  of relative frequencies within system organ classes and relative risks, as 
appropriate, will be presented.
When adjudication is required of major cardiovascular events, a summary  of those types of 
events as reported b y the investiga tor and confirmed by  adjudication will be provided.
Laboratory  data
The summary  of laboratory  evaluations will be presented for three groups of laboratory  tests 
(hematology , serum chemistry  and urinal ysis). Descriptive summary  statistics for the change 
from baseline to each study  visit will be presented. These descriptive summaries will be 
presented b y test group, laboratory test and treatment group. Change from baseline will only  be 
summarized for subjects with both baseline and post -baseline. 
For each parameter, the maximum change from baseline within each study  period will be 
evaluated analogously . 
In addition, shift tables will be provided for all parameters to compare a subject’s baseline 
laboratory  evaluation relative to the visit’s observed value. For the shift tables, the normal 
laboratory  ranges will be used to evaluate whether a particular laboratory  test value was normal, 
low, or high for each visit value relative to whether or not the baseline value was normal, low, 
or high. These summaries will be presented by  laboratory  test and treatment group. Shifts will 
be presented b y visit as well as for most extreme values post -baseline.

Novartis Confidential Page 85
Amended Protocol Version 02 Track Changes Protocol No. CAIN457F2366
 
 
Vital signs
Analy sis of the vital sign measurements using summary statistics for the change from baseline 
for each post-baseline visit will be performed. These descriptive summaries will be presented 
by vital sign and treatment group. Change from baseline will only  be summarized for subjects 
with both baseline and post -baseline values.

Novartis Confidential Page 86
Amended Protocol Version 02 Track Changes Protocol No. CAIN457F2366

Novartis Confidential Page 87
Amended Protocol Version 02 Track Changes Protocol No. CAIN457F2366
9.6 Interim analy ses
The primary  analysis may be conducted when all patients complete the Week 52 visit. In the 
case this analysis is conducted, all patients will have final data pertaining to the Week 52 
endpoints, thus no adjustment to the type I error will be made and the final analy sis after the 
last visit (Week 68) will include the data collected from the post -treatment follow -up period.
9.7 Sample size calculation
A famil y-wise error will be set to two-sided α=0.05 to control for type I error. The primary 
objective of secukinumab 300 mg versus adalimu mab with respect to ACR20 response at Week 
52 will be tested at a two sided 0.05 alpha level. 
An ACR20 response rate of about 50% for the TNFα inhibitor naïve without MTX use 
(monotherap y) population at week 48 was reported 
in Humira study  (Gladman 2007). The 
response on secukinumab 300 mg is estimated to be 62% in the TNFα inhibitor naïve 
monotherap y population based on the lower bound of 80% confidence interval of Meta -analysis 
results of the stud y FUT URE -2 (McInnes 2015 )and unpublished study FUTURE
-3.  With 425 
subjects per treatment group there would be approximately  94% power to detect a treatment 
difference of 12% at a two-sided 0.05 alpha level in ACR20 response rates (Chi Square test, 
NQuery  7.0) between secukinumab 300 mg and adalimumab in the evaluation of the primary  
efficacy  hypothesis 
at Week 52. The overall sample size will be 850 patient for a randomization 
ratio of 1:1 (secukinumab 300mg 425 patients, and adalimumab 425 patient). The estimated 

Novartis Confidential Page 88
Amended Protocol Version 02 Track Changes Protocol No. CAIN457F2366
power with the chosen sample size for other efficacy  endpoints based on the data available for 
adalimumab and meta -analy sis results of the study  FUTURE -2 and study  FUTURE -3 are 
summarized in Table 9 -2. The assumptions for power calculation in Table 9 -2are presented in 
Table 9-1.
Table 9-1 Assumption for sample size and po wer calculation
EndpointSecukinumab 
300mg expected 
valuesAdalimumab 
(N=76) observed 
values
ACR20 62% 50%
PASI90 63% 38% (N=40)
ACR50 49% 38%
HAQ -DI change* -0.59 (0.5) -0.4 (0.5)(N=61)
Resolution of 
enthesitis61%33%
*mean (standard deviation)
Sources: The value for Secukinumab is from the lower bound of 80% confidence interval of a meta -
analysis  based on FUTURE -2 and unpublished results from FUTURE -3 data, the values for other 
endpoints for Secukinumab are from the means of the same meta -analysis, the values for Adalimumab 
are from Humira® study ( Gladman 2007 ).
Based on Table 9-1, power calculation for superiority tests of different endpoints are presented 
below in Table 9-2.
Table 9-2 Power for superiority  tests for primary  and secondary  endpoints (two -
sided, α=0.05)
Endpoint Power* 
ACR20 (H1) 94%
PASI90 (H2) 99%
ACR50 (H3) 91%
HAQ -DI (H4) 99%
Resolution of enthesitis 
(H5)99%
* power does not consider dependence of the endpoints in the Testing Strategy, power for PASI90 and 
enthesitis is based on the assumption that a subset of half of the population (213 subjects per group) 
has data of these two endpoints.
10 Ethical considerations
10.1 Regulatory  and ethical compliance 
This clinical study  was designed and shall be implemented, executed and reported in accordance 
with the ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable 

Novartis Confidential Page 89
Amended Protocol Version 02 Track Changes Protocol No. CAIN457F2366
local regulations (including Europ ean Directive 2001/20/EC, US CFR 21, and Japanese 
Ministry  of Health, Labor, and Welfare), and with the ethical principles laid down in the 
Declaration of Helsinki.
10.2 Informed consent procedures 
Eligible subjects may only be included in the study after providing IRB/IEC -approved informed 
consent (witnessed, where required by law or regulation), or, if incapable of doing so, after such 
consent has been provided by a  legall y acceptable representative(s) of the subject. In cases 
where the subject’s representati ve gives consent, the subject should be informed about the study 
to the extent possible given his/her understanding. If the subject is capable of doing so, he/she 
must indicate assent by personall y signing and dating the informed consent document or a 
separate assent form. Informed consent must be obtained before conducting any  study -specific 
procedures (e.g. all of the procedures described in the protocol). The process of obtaining 
informed consent must be documented in the patient source documents. 
Novar tis will provide to investigators in a separate document a proposed informed consent form 
that complies with the ICH GCP guideline and regulatory  requirements and is considered 
appropriate for this study . Any changes to the proposed consent form suggested by the 
investigator must be agreed to by  Novartis before submission to the IRB/IE C, and a copy  of the 
approved version must be provided to the Novartis monitor after IRB/ IEC approval.
Women of child bearing potential must be informed that taking the study  treatment may involve 
unknown risks to the fetus if pregnancy  were to occur during the study  and agree that in order 
to participate in the study they  must adhere to the contraception requirement for the duration of 
the study , and for a minimum 16 weeks or longer if local label requires it (e.g. 20 weeks for 
secukinumab, 5 months for adalimumab in EU) after the last dose. If there is any  question that 
the subject will not reliably  compl y, they should not be entered in the stud y.
The study includes an optiona l PG ICF which requires a separate signature if the subject agrees 
to participate. It is required as part of this protocol that the Investigator presents this option to 
the subject. The process for obtaining consent should be exactly  the same as described above 
for the main informed consent.
Declining to participate in these PG assessments will in no way affect the patient’s ability  to 
participate in the main research stud y. 
In the event that Novartis wants to perform testing on the samples that are not de scribed in this 
protocol, additional I RB and/or IEC approval will be obtained. 
10.3 Responsibilities of the investigator and IRB/IEC
Before initiating a trial, the investigator/institution must obtain approval/favorable opinion from 
the IRB/IEC for the trial protocol, informed consent form, consent form updates, subject 
recruitment procedures (e.g., advertisements) and any other written information to be provided 
to subjects. Prior to study  start, the investigator is required to sign a protocol signature page 
confirming his/her agreement to conduct the study  in accordance with these documents and all 
of the instructions and procedures found in this protocol and to give access to all relevant data 
and records to Novartis monitors, auditors, Novartis Quality  Assurance representatives, 
designated agents of Novartis, IRBs/IECs, and regulatory  authorities as required. If an 

Novartis Confidential Page 90
Amended Protocol Version 02 Track Changes Protocol No. CAIN457F2366
inspection of the clinical site is requested by a regulatory  authorit y, the investigator must inform 
Novartis immediately  that this request has be en made.
10.4 Publication of study  protocol and results 
Novartis assures that the key design elements of this protocol will be posted in a publicl y 
accessible database such as clinicaltrials.gov. In addition, upon study  completion and 
finalization of the study report the results of this trial will be either submitted for publication 
and/or posted in a publicly  accessible database of clinical trial results.
11 Protocol adherence 
This protocol defines the study  objectives, the study procedures and the data to be co llected on 
study  participants. Additional assessments required to ensure safety  of subjects should be 
administered as deemed necessary  on a case by case basis. Under no circumstances is an 
investigator allowed to collect additional data or conduct any additional procedures for any 
research related purpose involving an y investigational drugs.
Investigators ascertain they will apply due diligence to avoid protocol deviations. If an 
investigator feels a protocol deviation would improve the conduct of the study  this must be 
considered a protocol amendment, and unless such an amendment is agreed upon by Novartis 
and approved by the IRB/IEC, it cannot be implemented. All significant protocol deviations 
will be recorded and reported in the CSR.
11.1 Protocol amendments 
Any change or addition to the protocol can onl y be made in a written protocol amendment that 
must be approved by Novartis, Health Authorities where required, and the IRB/IEC prior to 
implementation. Only  amendments that are intended to eliminate an apparent immediate hazard 
to patients/subjects may be implemented immediately  provided the health authorities are 
subsequently  notified by protocol amendment and the reviewing IRB/IEC is notified. 
Notwithstanding the need for approval of formal protocol amendments, the investigator is 
expected to take any immediate action required for the safet y of any patient included in this 
study , even if this action represents a deviation from the protocol. In such cases, the reporting 
requirements identified in Section 7 must be followed.

Novartis Confidential Page 91
Amended Protocol Version 02 Track Changes Protocol No. CAIN457F2366
12 References
References are available upon request.
Behrens F, Cañete JD, Olivieri I, et al (2015) Tumour necrosis factor inhibitor monotherap y vs 
combination with MTX in the treatment of PsA: a systematic review of the literature. 
Rheumatology  (Oxford); 54:915-26.
 
Bonafede M, Johnson BH, Fox KM, et al (2013) Treatment patterns with etanercept and 
adalimumab for psoriatic diseases in a real -world setting. J Dermatol Treat; 24:369 -73.
Cosenty x [package insert](2016). East Hanover NJ:Novartis. 
Cosenty x SmPC (2016). London.EMA.
Cella DF, Tulsky  DS, Gray  G, et al (1993) The Functional Assessment of Cancer Therap y  scale: 
Development and validation of the general measure. Journal of Clinical Oncology ; 11(3):570 -
9.
European Medicine Agency  (EMA) (2005) Guideline on clinical investigatio n of medicinal 
products for the treatment of psoriatic arthritis. London.
Felson DT, Anderson JJ, Boers M, et al (1995) American College of Rheumatology . 
Preliminary  definition of improvement in rheumatoid arthritis. Arthritis Rheum; 38:727 -35.
 
FitzGerald O, Helliwell P, Mease P, et al., (2012) Application of composite disease activity  
scores in psoriatic arthr itis to the PRESTA data set. Ann Rheum Dis; 71:358 -62. 
FitzGerald O, Winchester R. (2014) Emerging evidence for critical involvement of the 
interleukin -17 pathway  in both psoriasis and psoriatic arthritis. Arthritis Rheumatol; 66: 1077 –
80.
Fredriksson T, Pettersson U (1978) Severe psoriasis- oral therapy  with a new retinoid. 
Dermatologica; 157:238 -44.
Gladman D, Antoni C, Mease P, et al (2005) Psoriatic arthritis: epidemiology, clinical features, 
course, and outcome. Ann Rheum Dis; 64:ii14 –17. 
Gladman DD, Mease PJ, Ritchlin CT et al, (2007) Adalimumab for Long -Term Treatment of 
Psoriasis Arthritis. Arthritis Rheum; 56:476
- 88 
 
 
Gottlieb A, Griffiths CEM, Ho VC, et al (2005) Oral pimecrolimus in the treatment of moderate 
to severe chronic plaque -type psoriasis: a double -blind, multicentre, randomi zed dose-finding 
trial. Br J Dermatol; 152:1219-27.

Novartis Confidential Page 92
Amended Protocol Version 02 Track Changes Protocol No. CAIN457F2366
Heal y PJ, Helliwell PS (2008) Measuring clinical enthesitis in psoriatic arthritis: assessment of 
existing measures and development of an instrument specific to psoriatic arthritis. Arthritis 
Rheum; 59:68 6-91.
 
Helliwell PS, Fitzgerald O, Fransen J, et 
al (2013). The development of candidate composi te 
disease activity  and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis; 
72: 986-91. 
Humira [package insert](2016). North Chicago IL:Abbvie.
Humira SmPC (2016). London.EMA.
Kavanaugh A, Mease PJ, Gomez -Reino JJ, et al (2014) Treat ment of psoriatic arthritis in a 
phase 3 randomised, placebo -controlled trial with apremilast, an oral phosphodiesterase 4 
inhibitor. Ann Rheum Dis; 73: 1020–6.
Koch GG, 
Tangen CM, Jung JW, et al (1998) Issues for covariance analy sis of dichotomous 
and ordered categorical data from randomized clinical trials and non-parametric strategies for 
addressing them. Stat Med; 17: 1863 -
92.
Langley  RG, Elewski BE, Lebwohl M, et al (2014)  Secukinumab in plaque psoriasis --results 
of two phase 3 trials. N Engl J Med; 371:326-38.
Lubeck DP (2004) Patient- reported outcomes and their role in the assessment of rheumatoid 
arthritis. Pharmacoeconomics; 22:27 -38.
 
 
McInnes IB, Kavanaugh A, Gottlieb AB, et al (2013) Efficacy  and safet y of ustekinumab in 
patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double -blind, 
placebo- controlled PSUMMI T 1 trial. Lancet; 382: 780–9.
McInnes IB, Mease PJ, Kirkham B, et al (2015). Secukinumab, a human anti-interleukin -17A 
monoclonal antibody , in patients with psoriatic arthritis (FUTURE 2): a randomised, double -
blind, placebo -controlled, phase 3 trial. Lancet; 386: 1137–46
McInnes IB, Sieper J, Braun J, et al. (2014). Efficacy  and safet y of secukinumab, a fully human 
anti-interleukin -17A monoclonal antibody , in patients with moderate -to-severe psoriatic 
arthritis: a 24-week, randomised, double -blind, placebo -controlled, phase II proof - of-concept 
trial. Ann Rheum Dis; 73:349-56.
Mease PJ, McI nnes IB, Kirkham B, et al (2015) Secukinumab inhibition of interleukin -17A in 
patients with psoriatic arthritis. N Engl J Med; 373:1329 -39.
Nikiphorou E, Negoescu A, Fitzpatrick JD, et al (2014) Indispensable or intolerable? 
Methotrexate in patients with rheumatoid and psoriatic arthritis: a retrospective review of 
discontinuation rates from a large UK cohort. Clin Rheumatol; 33:609 -14.

Novartis Confidential Page 93
Amended Protocol Version 02 Track Changes Protocol No. CAIN457F2366
Rosen CF, Mussani F,Chandran V, et al (2012) Patients with psoriatic arthritis have worse 
quality  of life than those with psoriasis alone. Rheumatology  (Oxford); 51:571–6.
Schoels M. (2014) Psoriatic arthritis indices. Clin Exp Rheumatol; 32:S -109-12. 
Taylor W, Gladman D, Helliwell, et al (2006) Classification criteria for psoriatic arthritis: 
development of new criteria from a large international study . Arthritis Rheum; 54:2665 -73.
Thaçi D, Blauvelt A, Reich K, et al (2015) Secukinumab is superior to ustekinumab in clearing
skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled 
trial. J Am Acad Dermatol;73:400 -9.
Ware JE, Snow KK, Kosinki M, et al (1993) SF-36 Health Survey  Manual and interpretation 
guide. Boston, MA: The Health Institute, New England Medical Center.
Ware JE, Kosinki M, Bjorner JB, et al (2008) SF -36v2® Health Survey : Administration guide 
for clinical trial investigators. L incoln, RI: Qualit yMetric Incorporated.
Weisman S, Pollack CR, Gottschalk RW (2003) Psoriasis disease severity  measures: comparing 
efficacy  of treatments for severe psoriasis. J Dermatolog Treat; 14:158-65.
Yellen SB, Cella DF, Webster K, et al (1997) Measuring fatigue and other anemia -related 
symptoms with the Functional Assessment of Cancer Therapy  (FACT) measurement s ystem. J 
Pain Sy mptom Manage; 13:63 -74. 

Novartis Confidential Page 94
Amended Protocol Version 02 Track Changes Protocol No. CAIN457F2366
13 Appendix 1: The classification criteria for psoriatic arthritis 
(CASPAR)
To meet the Classification of Psoriatic Arthritis (CASPAR) criteria for diagnosis of psoriatic 
arthritis ( Taylor 2006), a subject must have inflammatory  articular disease (joint, spine or 
entheseal) and at least 3 points from the following 5 categorie
s:
Evidence of current psoriasis, a personal history  of psoriasis, or a famil y history  of psoriasis 
Current psoriasis is defined as psoriatic skin or scalp disease present today  as judged by a 
rheumatologist or dermatologist.* ( 2 points )
A personal history  of psoriasis is defined as a history  of psoriasis that may  be obtained from a 
patient, family  physician, dermatologist, rheumatologist, or other qualified health care provider. 
(1 points )
A family  history  of psoriasis is defined as a history  of psoriasis in a first-or second -degree 
relative according to patient report. ( 1points)
Typical psoriatic nail d ystrophy  including onycholy sis, pitting, and h yperkeratosis observed on 
current ph ysical examination ( 1 point )
A negative test result for the presence of rheumatoid factor by any method except latex (1 point )
Either current dacty litis, defined as swelling of an entire digit, or a history  of dactylitis recorded 
by a rheumatologist ( 1 point )
Radiographic evidence of juxta -articular new bone formation appearing as ill-defined 
ossification near joint margins (but excluding osteophy te formation) on plain radiographs of the 
hand or foot ( 1 point )
Total score: 
(The CASPAR criteria eCRF will autopopulate the total number of points of the CASPAR 
criteria met by the subject. If the total score ≥ 3, the subject meets CASPAR criteria for PsA 
diagnosis.)
* Current psoriasis is assigned a score of 2; all other features are assigned a score of 1

Novartis Confidential Page 95
Amended Protocol Version 02 Track Changes Protocol No. CAIN457F2366
14 Appendix 2: Guidelines for administering the questionnaires 
for patient reported outcomes
Before trial start
Study  coordinators should familiarize themselves with the PRO questionnaire(s) in the trial and 
identify  any items where a patient’s response might highlight issues of potential concern.
 
 
Before completion
Subjects should be provided with the correct questionnaire at the appropriate visits and in the 
appropriate language
Subjects should have adequate space and time to complete the forms
Patients should be provided with a firm writing surface (such as a table or a clip board)
Questionnaire should be administered before the clinical examination
During completion
Administrator may  clarify  the questions but should not influence the response
Only  one response for each question
Also see “Addressing Problems and Concerns”
After completion
Check for completeness and not for content*
Data should be sent from the eCRF / e lectronic device
Data should be reviewed by  Investigator for AEs
*However, any response which may directl y impact or reflect the patient’s medical condition 
(e.g. noting of depression) should be communicated by the study  coordinator to the investigator).
Addressing Problems and Concerns
Occasionall y a patient may have concerns or questions about the questionnaires administered. 
Guidance related to some of the most common concerns and questions are given below.
The patient does not want to complete the quest ionnaire(s)
Tell the patient that completion of the questionnaire(s) is voluntary . The goal is to better 
understand the physical, mental and social health problems of patients. Emphasize that such 
information is as important as any other medical informatio n and that the questionnaire(s) is 
simple to complete. Suggest that the questionnaire(s) may be different from anything the 
respondent has filled in the past. If the patient still declines, retrieve the questionnaires. Record 
the reason for the decline and thank the patient.

Novartis Confidential Page 96
Amended Protocol Version 02 Track Changes Protocol No. CAIN457F2366
The patient is too ill or weak to complete the questionnaire(s)
In these instances, the coordinator may obtain patient responses by reading out loud each 
question, followed by the corresponding response categories, and entering the patient’s 
response. No help should be provided to the patient by any person other than the designated 
study  coordinator. The coordinator should not influence patient responses. The study 
coordinator cannot translate the question into simpler language and has t o be read verbatim.
The patient wants someone else to complete the questionnaire(s)
In no case should the coordinator or anyone other than the patient provide responses to the 
questions. Unless specified in the study  protocol, proxy data are not an accepta ble substitute for 
patient self-report. Patients should be discouraged from asking a famil y member or friend for 
help in completing a questionnaire.
The patient does not want to finish completing the questionnaire(s)
If non-completion is a result of the patient having trouble understanding particular items, ask 
the patient to explain the difficulty. Re -read the question for them verbatim but do not rephrase 
the question. If the respondent is still unable to complete the questionnaire, accept it as 
incomplet e. Thank the patient.
The patient is concerned that someone will look at his/her responses
Emphasize that 
all responses are to be kept confidential. Point out that their names do not appear 
anywhere on the questionnaire, so that their results will be linked with an ID number and not 
their name. Tell the patient that his/her answers will be pooled with other patients’ answers and 
that they  will be analy zed as a group rather than as individuals. Tell the patient that completed 
forms are not routinel y shared with treating staff and that their responses will only be seen by 
you (to check for completeness) and by the investigator. Any response which may directl y 
impact on or reflect their medical condition (e.g. noting of severe depression) will be 
communica ted b y the coordinator to the ph ysician.
The patient asks the meaning of a question/item
While completing the questionnaire, some patients might ask the meaning of specific items so 
that they  can better understand and respond. If this happens, assist the p atient by  rereading the 
question for them verbatim. If the patient asks to interpret the meaning of an item, do not try to 
explain it, but suggest that he/she use his/her own interpretation of the question. Patients should 
answer the questions based on wha t they think the questions mean.
A General Information about all questionnaire(s):
All questionnaires have to be completed by the patients in their local languages using an 
electronic device. The questionnaires should be completed by the patients in a quiet area free 
from disturbance, and before any visit assessments. Patients should receive no help from famil y 
members; if questions cannot be answered alone (due to problems with reading or 
understanding), then the doctor or nurse should read the questions and record the patient’s 
responses without influencing their answers. The information provided is strictly  confidential 
and will be treated as such. If a patient has missed a question or given more than one response 

Novartis Confidential Page 97
Amended Protocol Version 02 Track Changes Protocol No. CAIN457F2366
per question, then this should be brought to patient. Incomplete questions should not be accepted 
without first encouraging the patient to complete unanswered questions.
The investigator must complete the patient/visit information on the electronic device and ensure 
that the center number, patient’s number and initials are identical to the CRF. As there are no 
source data for this questionnaire, the data queries will be restricted to patient/visit information.

Novartis Confidential Page 98
Amended Protocol Version 02 Track Changes Protocol No. CAIN457F2366
15 Appendix 3: A merican College of Rheumatology  (ACR) 
Measures and Criteria of Response
Num ber of tender joints
Seventy -eight joints (78) are scored as either tender or not tender: 8 distal interphalangeal, 10 
proximal interphalangeal, 10 metacarpophalangeal and 2 first carpometacarpal joints of the 
hands, 8 distal interphalangeal, the 10 metatarsophalangeal and 10 proximal interphalangeal 
joints of the feet, the 2 wrists, 2 elbows, 2 shoulders, 2 acromioclavicular, 2 sternoclavicular, 2 
temporomandibular, 2 hips, 2 knees, 2 talo- tibial, and 2 mid- tarsal joints.
Joint tenderness is to be scored p resent (1) or absent (0).
Number of swollen joints
Joints are to be scored as either swollen (1) or not swollen (0). The 76 joints to be examined for 
swelling are the same as those examined for tenderness, however excluding both hip joints.
Patient's asses sment of PsA pain
On a 100 mm non -anchored visual analog scale, from no pain to unbearable pain.
Patient's global assessment of disease activity
On a 100 mm non-anchored visual analog scale, from no arthritis activity  to maximal arthritis 
activity , after the question "Considering all the ways your arthritis affects you, draw a line on 
the scale for how well y ou are doing".
Physician's global assessment of disease activity
On a 100 mm non-anchored visual analog scale, from no arthritis activity  to maximal arthritis 
activity .
Patient's assessment of phy sical function
Health Assessment Questionnaire –HAQ -DI©ACR20/50/
A patient will be considered as improved according the ACR20 criteria* if she/he has at least
20% improvement in
the two following measures:
Tender joint count
Swollen joint count
and at least 3 of the following 5 measures:
Patient's assessment of pain
Patient's global assessment of disease activity
Physician's global assessment of disease activity
Health Assessment Questionnaire (HAQ©) score
C-reactive protein (CRP)/Ery throcy te Sedimentation Rate (ESR).
ACR50 = 50% improvement in at least 3 of the 5 measures and 50% improvement in the 
swollen and tender joint count.

Novartis Confidential Page 99
Amended Protocol Version 02 Track Changes Protocol No. CAIN457F2366
 
Reference: (Felson 1995)

Novartis Confidential Page 100
Amended Protocol Version 02 Track Changes Protocol No. CAIN457F2366

Novartis Confidential Page 101
Amended Protocol Version 02 Track Changes Protocol No. CAIN457F2366
17 Appendix 5: The Psoriasis A rea and Severity  Index (PA SI)
The PASI  is a sy stem used for assessing and grading the severity  of psoriatic lesions and their 
response to therap y. The PASI  produces a numeric score that can range from 0 to 72. The 
severit y of disease is calculated as follows. In the PASI system, the body  is divided into 4 
regions: the head (h), trunk (t), upper extremities (u), and lower extremities (l), whi ch account 
for 10%, 30%, 20% and 40% of the total BSA, respectivel y. Each of these areas is assessed 
separately  for erythema, induration and desquamation (scaling), which are each rated on a scale 
of 0 to 4. The scoring system for the signs of the disease (erythema, induration, and 
desquamation (scaling)) are:
0 = none; 1= slight; 2 = moderate; 3 = severe; and 4 = very  severe. 
The scale for estimating the area of involvement for psoriatic lesions is outlined below.
0 = no involvement
1 = 1% to 9% involveme nt
2 = 10% to 29% involvement
3 = 30% to 49% involvement
4 = 50% to 69% involvement
5 = 70% to 89% involvement
6 = 90% to 100% involvement
To help with the area assessments, the following conventions should be noted:
the neck is considered part of the head
the axillae and groin are part of the trunk
the buttocks are part of the lower extremities
The PASI formula is: PASI  = 0.1 (Eh + Ih + Dh) Ah + 0.3 (Et +It+ Dt) At+ 0.2 (Eu + Iu + Du) 
Au+ 0.4 (El +II+ Dl) AI (where E= ery thema, I = induration, D = desquama tion and A = area)
Table 17-1 PASI Scoring Worksheet
Head Upper extremities TrunkLower 
extremities
Redness †
Thickness †
Scale †
Sum of rows 1, 2, and 3
Area score ‡
Score of row 4 x row 5 
x the area multiplierRow 4 x row 5 
x 0.1Row 4 x row 5
x 0.2Row 4 x row 5
x 0.3Row 4 x row 5
x 0.4
Sum row 6 for each 
column for PASI score

Novartis Confidential Page 102
Amended Protocol Version 02 Track Changes Protocol No. CAIN457F2366
a. Divide body into four areas: head, arms, trunk to groin, and legs to top of buttocks.
b. Generate an average score for the erythema, thickness, and scale for each of the 4 areas (0=clear, 1 -
4=increasing severity).
c. Sum scores of erythema, thickness, and scale for each of the 4 area.
d. Generate a percentage fo r skin covered w ith psoriasis for each area and convert that to a 0 -6 scale. ‡
e. Multiply score of item c above times item d above for each area and multiply that by 0.1, 0.2, 0.3 and 0.4 
for head, arms, trunk, and legs, respectively.
f. Add these scores to get the PASI score.
†Erythema, thickness, and scale are measured on a 0 -4 scale (none, slight, mild, moderate, severe)
‡Area scoring criteria (score: % involvement).
0: 0% (clear)
1: <10%
2: 10 -<30%
3: 30 -<50%
4: 50 -<70%
5: 70 -<90%
6: 90- 100%
Derived from Feldman SR, Krueger GG (2005). Psoriasis assessment tool in clinical trials. Ann Rheum Dis; 
64 (Suppl 2);ii65 -8, ii69 -73.

Novartis Confidential Page 103
Amended Protocol Version 02 Track Changes Protocol No. CAIN457F2366
18 Appendix 6: Liver event and laborator y trigger definitions 
and follow-up requirements
Table 18-1 Liver Event and Laboratory  Trigger Definitions
Definition/ threshold
LIVER 
LABORATORY 
TRIGGERS3 x ULN < ALT / AST 5 x ULN
1.5 x ULN < TBL  2 x ULN
LIVER EVENTS ALT or AST > 5 × ULN
ALP > 2 × ULN (in the absence of known bone pathology)
TBL  > 2 × ULN (in the absence of known Gilbert syndrome)
ALT or AST > 3 × ULN and INR > 1.5 
Potential Hy’s Law cases (defined as ALT or AST > 3 × ULN and TBL > 2 × 
ULN [mainly conjugated fraction] without notable increase in ALP to > 2 × ULN)
Any clinical event of jaundice (or equivalent term)
ALT or AST > 3 × UL N accompanied by (general) malaise, fatigue, abdominal 
pain, nausea, or vomiting, or rash with eosinophilia
Any adverse event potentially indicative of a liver toxicity * 
* These events cover the following: hepatic failure, fibrosis and cirrhosis, and other liver damage -related 
conditions; non -infectious hepatitis; benign, malignant and unspecified liver neoplasms
TBL: total bilirubin; ULN: upper limit of normal
Table 18-2 Follo w up Requirements for Liver Events and Laboratory  Triggers
Criteria Actions required Follow -up mon itoring
Potential Hy’s 
Law caseaDiscontinue the study drug immediately
Hospitalize, if clinically  appropriate
Establish causality
Complete liver eCRFALT, AST, TBL, Alb, PT/INR, ALP 
and γGT until resolutionc(frequency 
at investigator discretion)
ALT or AST
> 8 × ULN Discontinue the study drug immediately
Hospitalize if clinically  appropriate
Establish causality
Complete liver eCRFALT, AST, TBL, Alb, PT/INR, ALP 
and γGT until resolutionc(frequency 
at investigator discretion)
> 3 × ULN and 
INR > 1.5Discontinue the study drug immediately
Hospitalize, if clinically  appropriate
Establish causalityALT, AST, TBL, Alb, PT/INR, ALP 
and γGT until resolutionc(frequency 
at investigator discretion)

Novartis Confidential Page 104
Amended Protocol Version 02 Track Changes Protocol No. CAIN457F2366
Criteria Actions required Follow -up mon itoring
Complete liver eCRF
> 5 to ≤ 8 × ULN Repeat LFT within 48 hours
If elevation persists, continue follow -
up monitoring
If elevation persists for more than 2 
weeks , discontinue the study  drug
Establish causality
Complete liver eCRFALT, AST, TBL, Alb, PT/INR, ALP 
and γGT until resolutionc(frequency 
at investigator discretion)
> 3 × ULN 
accompanied by 
symptomsbDiscontinue the study drug immediately
Hospitalize if clinically  appropriate
Establish causality
Complete liver eCRFALT, AST, TBL, Alb, PT/INR, ALP 
and γGT until resolutionc(frequency 
at investigator discre tion)
> 3 to ≤ 5 × ULN 
(patient is 
asymptomatic)Repeat LFT within the next week
If elevation is confirmed, initiate 
close observation of the patientInvestigator discretion
Monitor LFT within 1 to 4 weeks 
ALP (isolated)
> 2 × ULN (in the 
absence of known 
bone pathology)Repeat LFT within 48 hours
If elevation persists, establish 
causality
Complete liver eCRFInvestigator discretion
Monitor LFT within 1 to 4 weeks 
or at next visit
TBL (isolated)
> 2 × ULN (in the 
absence of known 
Gilbert syndrome)Repeat LFT within 48 hours
If elevation persists, discontinue the 
study  drug immediatel y
Hospitalize if clinically  appropriate
Establish causality
Complete liver eCRFALT, AST, TBL, Alb, PT/INR, ALP 
and γGT until resolutionc(frequency 
at investi gator discretion)
Test for hemol ysis (e.g., 
reticulocy tes, haptoglobin, 
unconjugated [indirect] bilirubin)
> 1.5 to ≤ 2 × 
ULN
(patient is 
asymptomatic)Repeat LFT within the next week
If elevation is confirmed, initiate 
close observation of the patient Investigator discretion
Monitor LFT within 1 to 4 weeks 
or at next visit
Jaundice Discontinue the study drug immediately
Hospitalize the patientALT, AST, TBL, Alb, PT/INR, ALP 
and γGT until resolutionc(frequency 
at investigator discretion)

Novartis Confidential Page 105
Amended Protocol Version 02 Track Changes Protocol No. CAIN457F2366
Criteria Actions required Follow -up mon itoring
Establish causality
Complete liver eCRF
Any AE 
potentially 
indicative of a 
liver toxicity*Consider study drug interruption or 
discontinuation 
Hospitalization if clinically  
appropriate
Establish causality
Complete liver eCRFInvestigator discretion
* These events cover the following: hepatic failure, fibrosis and cirrhosis, and other liver damage -related 
conditions; non -infectious hepatitis; benign, malignant and unspecified liver neoplasms
TBL: total bilirubin; ULN: upper limit of normal
a Elevated ALT/AST > 3 × ULN and TBL > 2 × ULN but without notable increase in ALP 
to > 2 × ULN
b (General) malaise, fatigue, abdominal pain, nausea, or vomiting, or rash with eosinophilia 
c Resolution is defined as an outcome of one of the following: (1) return to baseline values , 
(2) stable values at three subsequent monitoring visits at least 2 weeks apart, (3) remain at 
elevated level after a maximum of 6 months, (4) liver transplantation, and (5) death.

Novartis Confidential Page 106
Amended Protocol Version 02 Track Changes Protocol No. CAIN457F2366
19 Appendix 7: Clinically  notable laboratory  values
The following guidance will be used to define expanded limits and notable abnormalities 
of key  laboratory  outcomes. 
Clinically  notable values will be forwarded to Novartis in the same time as sent to the 
investigators. An y intervention based on these laboratory  values should be discussed with 
Novartis personnel.
Table 19-1 Clinically  notable laboratory  values
Laboratory variable Notable criteria
Liver function and related variables
SGOT (AST) >3 x ULN
SGPT (ALT) >3 x ULN
Bilirubin >2 x ULN
Alkaline phosphatase >2.5 x ULN
Renal function, metabolic and electrolyte variables
Creatinine (serum) >2 x ULN
Hematology variables
Hemoglobin 20 g/L decrease from Baseline
Platelet count <100 x 109/L
White blood cell count <0.8 x LLN
Neutrophils <0.9 x LLN
